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ABSTRACT
The RET receptor tyrosine kinase is a classic example of phenotypic heterogeneity.
Gain-of-function mutations of RET are associated with human cancer. Gene
rearrangements juxtaposing the tyrosine kinase domain of RET to heterologous
gene partners have been found in sporadic papillary carcinomas of the thyroid
(PTC). These rearrangements generate the chimeric RET/PTC oncogenes. In
germline, point mutations of RET are responsible for multiple endocrine neoplasia
type 2 (MEN 2A, MEN 2B, and familial medullary thyroid cancer FMTC). Both
MEN 2 mutations and PTC gene rearrangements potentiate the intrinsic tyrosine
kinase activity of RET and, ultimately, the RET downstream signalling events.
Loss-of-function mutations of RET cause Hirschsprung’s disease (HSCR) or 
colonic aganglionosis. Ret-deficient mice display renal agenesis or severe
dysgenesis and lack of enteric neurons.
RET receptor tyrosine kinase and glial cell line-derived neurotrophic factor
(GDNF) family receptor 1 (GFR1) form a signalling receptor complex for
GDNF. It can also signal via GFR1 in a RET-independent manner. In complex
with GFR1, neural cell adhesion molecule (NCAM) acts as an alternative receptor
for GDNF and other GDNF family ligands (GFLs).
The present study was undertaken to characterise the interaction of RET
with the Shc adaptor protein. We found that Shc is recruited and activated by the
oncogenic forms of RET, namely RET/PTC2, RET-MEN 2A, and RET-MEN 2B,
but not by unstimulated RET. Both phosphotyrosine binding domains of Shc, PTB
and SH2, interact with RET/PTC2 in vitro, PTB domain having a higher affinity.
We showed that Tyr1062 of RET (corresponding to Tyr586 of RET/PTC2) is the
docking site for Shc, and that it is required for RET transforming activity.
However, Tyr1062 was differentially needed by the two RET isoforms (RET9 and
RET51) to promote cell scattering of the SK-N-MC neuroepithelioma cell line and
branching tubule formation in the epithelial MDCK cell line, indicating that the
RET51 isoform-specific Tyr1096 may substitute for some Tyr1062 functions.
Furthermore, the RET transforming activity, as well as the ability of the RET
receptor to induce cell motility, migration, branching morphogenesis, proliferation
and apoptosis, were analysed in MDCK cells expressing RET gain-of-function or
loss-of-function mutations associated with MEN 2 or HSCR. We provided an
explanation for the dual phenotypic mutation at Cys620 of RET, which co-
segregates with both MEN 2 and HSCR in a sizeable fraction of families. The same
cell model was used to study RET-independent signalling of GDNF via GFR1.
GDNF partially restored ureteric branching in kidney culture of Ret-deficient mice
with severe renal hypodysplasia.
Key words: RET, GDNF, Shc, thyroid carcinoma, MEN 2, Hirschsprung’s disease, 
oncogene
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1. REVIEW OF THE LITERATURE
1.1 RET RECEPTOR TYROSINE KINASE
1.1.1 RET gene and RET proteins
The RET oncogene was identified by Takahashi and co-workers, who reported a
novel gene re-arrangement with transforming activity in NIH 3T3 cells transfected
with human lymphoma DNA (Takahashi et al., 1985). The transforming gene
resulted from a recombination event between two unlinked DNA sequences that
occurred during the transfection process; hence the name RET, for “rearranged
during transfection”. The resulting chimeric gene encoded a fusion protein 
comprising an N-terminal region with a dimerising motif fused to a new tyrosine
kinase (TK) domain. Subsequently, the name RET has been retained to designate
the gene coding for the tyrosine kinase domain of this fused oncogene. The human
RET gene lies on the chromosome band 10q11.2 (Ishizaka et al., 1989) and
comprises 21 exons. Homologues of RET have been identified in higher and lower
vertebrates, as well as in the fruit fly, Drosophila melanogaster (Hahn and Bishop,
2001).
RET encodes a transmembrane receptor of the tyrosine kinase (TK) family
of proteins. RET protein is composed of three domains; an extracellular ligand-
binding domain with four cadherin-like repeats and a cysteine-rich domain, a
hydrophobic transmembrane region, and a cytoplasmic domain with a conserved
TK domain split by the insertion of 27 amino acids (Takahashi and Cooper 1987;
Takahashi et al., 1988; Takahashi et al., 1989; Iwamoto et al., 1993; Anders et al.,
2001). Cadherins are Ca2+-dependent cell-cell adhesion proteins whose adhesive
properties depend on repeated modules (cadherin domains) of about 110 residues in
the extracellular region. A Ca2+-binding site is often present in between each of the
domains. Cadherins comprise a large and divergent superfamily. The peculiar
organisation of the extracellular region of RET with four repeats of cadherin
domain and the ability to bind Ca2+ ions place RET as a distant member of the
cadherin superfamily. A fascinating model suggests that RET may have arisen by
the recombination of an ancestral cadherin with a tyrosine kinase gene (Anders et
al., 2001). Twenty seven of 28 cysteine (Cys) residues in the cysteine-rich domain
are conserved among species indicating a critical role for these residues in the
formation of correct intramolecular disulfide bonds (Ponder, 1999). The
extracellular portion of the molecule contains several glycosylation sites
(Takahashi et al., 1991). The fully glycosylated 170 kDa form is the fully mature
version of the receptor and is present on the cell membrane. The 150 kDa form is a
maturation intermediate which lacks glycosylation and is present only in the
endoplasmic reticulum (Takahashi et al., 1993).
Three isoforms of RET are generated by alternative 3splicing (Tahira et
al., 1990; Myers et al., 1995). The long, intermediate, and short RET isoforms,
which differ by 51, 43, and 9 amino acids in the C-terminus, are referred to as
RET51, RET43, and RET9, respectively. The two major isoforms RET51 and
RET9 are highly conserved over a broad range of species (Carter et al., 2001)
12
(Fig.1). RET51- and RET9-associated signalling complexes are markedly different,
suggesting that distinct isoforms can exert different roles in the physiological
functions of RET (Tsui-Pierchala et al., 2002a). Mice lacking the long RET
isoform (RET51) are normal, whereas mice lacking the short isoform (RET9) have
renal malformations and enteric aganglionosis. Only RET9 is able to rescue the
phenotype of the Ret-null mice (de Graaff et al., 2001; Srinivas et al., 1999). On
the other hand, only RET51 but not RET9 promotes the survival and tubulogenesis
of mouse inner-medullary collecting duct cells, suggesting that RET51 signalling
may contribute to the differentiation during late kidney morphogenesis (Lee et al.,
2002).
Figure 1. Schematic structure of the two major RET splicing isoforms,
RET51 and RET9. SP, signal peptide; CAD, cadherin domain; CYS, cysteine-rich
domain; TM, transmembrane domain; TK, tyrosine kinase domain.
1.1.2 RET is a functional receptor for GDNF-family ligands (GFLs)
RET is the signalling component of a multimolecular complex that binds growth
factors of the glial cell line-derived neurotrophic factor (GDNF) family. GDNF-
family ligands (GFLs) bind RET in conjunction with glycosylphosphatidyl inositol
(GPI)-membrane anchored co-receptors designated GDNF-family receptor-α 
(GFRα). RET remained an orphan receptor until several groups discovered that 
GDNF is a ligand for the RET signalling complex (Durbec et al., 1996a; Trupp et
al., 1996; Jing et al., 1996; Treanor et al., 1996; Vega et al., 1996). Thereafter,
other members of the GDNF family including neurturin (NRTN), persephin
(PSPN), and artemin (ARTN) (Kotzbauer et al., 1996; Milbrandt et al., 1998;
Baloh et al., 1998) were characterised and shown to bind and activate RET
(reviewed by Airaksinen et al., 1999; Saarma and Sariola 1999; Baloh et al., 2000;
Saarma 2000). GDNF was purified in 1993 as a growth factor promoting the
survival of embryonic midbrain dopaminergic neurons in vitro and in vivo; these
RET51
RET9
SP CAD CYS TM TK
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are the neurons that degenerate in Parkinson’s disease (Lin et al., 1993; Tomac et
al., 1995). Subsequently, it was shown that GDNF is also a very potent trophic
factor for spinal motoneurons (Henderson et al., 1994; Zurn et al., 1994;
Oppenheim et al., 1995; Yan et al., 1995) and central noradrenergic neurons
(Arenas et al., 1995). In addition, GDNF promotes the survival and regulates the
differentiation of all classes of peripheral neurons, namely many subpopulations of
sympathetic, parasympathetic, sensory and enteric neurons (Buj-Bello et al., 1995;
Ebendal et al., 1995; Trupp et al., 1995; reviewed by Airaksinen et al., 1999;
Manié et al., 2001; Airaksinen and Saarma, 2002). Outside the nervous system,
GDNF has important roles as a morphogenetic factor in developing kidney and in
the differentiation of spermatogonia (Pichel et al., 1996; Moore et al., 1996; Sainio
et al., 1997; Sariola and Saarma, 1999; Meng et al., 2000). GFLs are structurally
closely related, sharing about 40% identity at the amino acid level. They belong to
the transforming growth factor-(TGF-) superfamily. Despite low amino acid
sequence homology, GDNF and other structurally characterised members of the
TGF-superfamily have similar conformation (Ibáñez, 1998). They all belong to
the “cystine knot” protein family, and they function as homodimers. Typically for
many secreted proteins, GFLs are produced in the form of a precursor, preproGFL.
The signal sequence is cleaved upon secretion, and activation of the proGFL
probably occurs by proteolytic cleavage. GFLs seem to bind heparan-sulphate side
chains of extracellular-matrix (ECM) proteoglycans, which target them to the ECM
and raise their local concentration (Hamilton et al., 2001; reviewed by Airaksinen
and Saarma, 2002).
The high afinity binding of GDNF to RET is mediated by GFRα1 (Jing et
al., 1996; Treanor et al., 1996). The primary ligands for the co-receptors GFRα2, 
GFRα3, and GFRα4 are NRTN, ARTN, and PSPN, respectively (Fig. 2) (reviewed 
by Airaksinen et al., 1999; Saarma and Sariola 1999; Baloh et al., 2000). However,
signs of cross-talk between ligands (GDNF, NRTN, ARTN) and co-receptors
(GFRα1, GFRα2, GFRα3) have been observed in vitro (Baloh et al., 1997; Jing et
al., 1997; reviewed by Saarma 2000). Mammalian GFRα4 binds only PSPN and its 
structure significantly differs from other GFRreceptors (Lindahl et al., 2001).
The downstream signalling pathways are thought to be mostly common for all
GDNF family members since al GFRαs bind to and activate the same tyrosine 
kinase and induce coordinated phosphorylation of the same four key RET tyrosines
(Tyr905, Tyr1015, Tyr1062 and Tyr1096) with similar kinetics (Coulpier et al.,
2002).
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Figure 2. GDNF-family ligands (GFLs) and their receptors. Homodimeric
GFLs activate the transmembrane RET tyrosine kinase by binding with high
affinity to different GPI-linked GFR receptors. Binding of the ligand-GFR
complex to RET triggers its homodimerisation, transport to lipid rafts,
phosphorylation of tyrosine residues and subsequently intracellular signalling.
Solid arrows indicate the preferred functional ligand-receptor interaction, dotted
arrows indicate putative cross-talk. GFRproteins are attached to the plasma
membrane through a GPI-anchor and consist of three, or two in the case of GFR4,
globular cysteine-rich domains. GFR, GDNF-family receptor-α; NRTN, 
neurturin; ARTN, artemin; PSPN, persephin. (Modified from Sariola and Saarma,
2003).
1.1.3 RET-dependent GFLs signalling
RET is unable to bind GDNF on its own but it binds to a complex of GDNF and
GFRα1 (Jing et al., 1996; Treanor et al., 1996). Other members of the GFLs bind
to RET with the aid of diferent members of the GFRα family (reviewed by 
Airaksinen et al., 1999). The GFLs first form a high-affinity complex with one of
the four GFRα proteins. The complex, containing GFL and GFRα homodimers, 
then brings two molecules of RET together, triggering transphosphorylation of
specific tyrosine residues in their tyrosine kinase domains, and intracellular
signalling (reviewed by Airaksinen et al., 1999; Sariola and Saarma, 2003).
However, GDNF mutants that are deficient in GFRα1 binding are able to activate 
RET, indicating that at least some RET molecules are weakly associated with
GFRα1 before GDNF binding (Eketjäll et al., 1999).
RET
GFR1
GDNF NRTN ARTN PSPN
GFR2 GFR3
GFR4
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RET activation affects different downstream targets inside and outside lipid
rafts, which are special membrane structures of sphingolipids and cholesterol
packed into moving platforms within the lipid bilayer (reviewed in Simons and
Ikonen, 1997; Ikonen and Simons, 1998). Lipid rafts are proposed to serve as
essential signalling compartments in the cell membrane (Simons and Toomre,
2000). They are important for cell adhesion, axon guidance and synaptic
transmission. GPI-anchored proteins, certain transmembrane proteins, doubly
acylated proteins such as cytoplasmic Src-family kinases, and cholesterol-linked
and palmitoylated proteins are enriched in the rafts. The GFRα proteins, by the 
virtue of their GPI-anchors, also localise to lipid rafts (Poteryaev et al., 1999).
Current experimental data favour two models for RET activation. In cells co-
expressing RET and GFRα1, inactive RET is outside of the lipid rafts, and only 
upon GDNF stimulation does GFRα1 recruit RET into lipid rafts (cis signalling,
Fig. 3A). GFLs induce GFRα dimerisation. The high afinity of the GFL-GFRα 
complex to RET rapidly “drags” RET to the rafts and promotes its dimerisation, 
independently of its tyrosine kinase activity (Tansey et al., 2000; reviewed by
Airaksinen and Saarma, 2002).
GFRαs are widely expressed also in tissues lacking RET, suggesting
alternative signaling routes in the “ectopic” sites of GFRα expression (Trupp et al.,
1997; Yu et al., 1998). GFRαs can bind ligands and activate RET also in soluble 
form or when immobilised on agarose beads (Jing et al., 1996; Treanor et al., 1996;
Klein et al., 1997; Yu et al., 1998; Worley et al., 2000). GFRαs are usualy bound 
to the plasma membrane, but cleavage by an unknown phospholipase or protease
can produce soluble forms of these co-receptors. Biologically active soluble
GFRα1 (sGFRα1) is released by cultured neurons, neuronal cels, Schwann cels, 
and injured sciatic nerve (Worley et al., 2000; Paratcha et al., 2001). Alternative
splicing may also produce soluble forms, at least of GFRα4 (Lindahl et al., 2001).
Soluble GFRα1 may capture and loosen GFLs from the extracellular matrix space
and then present these factors in trans to RET-expressing cells (trans signalling,
Fig. 3B) (Trupp et al., 1997; Yu et al., 1998). Activation of RET in trans also
results in the mobilisation of RET to lipid raft even in cells that lack endogenous
GPI-anchored GFRα1. Recruitment of RET signaling intrans is slower and more
sustained than recruitment in cis, and requires an active RET tyrosine kinase,
suggesting the involvement of intracellular events (Paratcha et al., 2001; reviewed
by Paratcha and Ibáñez, 2002; Tsui-Pierchala et al., 2002b). During trans
signalling, RET may first be activated outside rafts and is then recruited into the
raft membrane compartments. Ligand activated RET is preferentially associated
with the adaptor Shc outside rafts, and with FGF receptor substrate 2 (FRS2)
within the rafts (Paratcha et al., 2001). cis and trans signalling of RET activate
downstream pathways with different kinetics, and both mechanisms can cooperate
to achieve optimal signalling in neurons co-expressing GFRα1 and RET (Paratcha 
et al., 2001). Expression studies of GDNF and its receptors indicate that many
GDNF-responsive neurons expressing both RET and GFRα1 project to sites rich in 
GFRα1 expression, suggesting that they may normally be exposed to both cis and
trans signalling in vivo (Trupp et al., 1997; Yu et al., 1998).
Whether GFLs/GFRαs other than GDNF/GFRα1 activate RET both in cis
and in trans, is poorly known. For example, GFR4, which mediates PSPN-
induced phosphorylation of RET, has a weak capacity to recruit RET into lipid
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rafts. In spite of this, PSPN-GFR4 promotes neurite outgrowth and survival of
cerebellar granule neurons. It is possible that GFR4 differs from GFRand
possibly the other co-receptors in the interaction with cell surface proteins (Yang et
al., 2004).
Figure 3. Cis vs. trans activation of RET signalling. (A) In the cis model of RET
activation, GPI-anchored GFRα1 dimers, located into lipid rafts, first bind a GDNF
dimer with high affinity. RET is then recruited to the GDNF-GFRcomplex 
within the raft compartment. (B) GDNF binds to soluble GFR1in the trans model
of RET activation. The GDNF-sGFRcomplex is then presented to RET, 
triggering RET activation. Activated RET preferentially associates with Shc
outside the rafts, and predominantly associates with FRS2 within the rafts.
Unphosphorylated (Y) and phosphorylated (Y*) tyrosine residues are indicated.
A
B
Y**Y**
GDNF
sGFR1
FRS
Y* Y*
Shc
GFR1
RET
GDNF
membrane
Y
raft
Y* Y*
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The neurotrophic effect of GDNF in vitro and in vivo requires TGF-
(Peterziel et al., 2002). Blocking the ERK/MAPK pathway inhibits this cooperative
effect, whereas inhibition of the PI3K signalling does not. Pre-treatment of primary
neuronal cultures with TGF-confers GDNF responsiveness on the cells. This is
not due to up-regulation of GDNF receptor mRNA and proteins but to TGF--
induced recruitment of the GFRα to the plasma membrane or changes in 
conformation and the affinity of the GFRα towards the ligand. In the absence of 
TGF-, GDNF supports neuronal survival in the presence of the soluble form of
GFRα. TGF- is thus involved in membrane translocation of the GFRα1 and in a 
novel way regulates GDNF signalling and its neurotrophic effects (Peterziel et al.,
2002). Heparan sulphate glycosaminoglycans are also required for RET-dependent
GDNF signalling (Barnett et al., 2002; Tanaka et al., 2002). Without heparan
sulphate GDNF-dependent RET phosphorylation, GDNF-induced axonal growth
and scattering of epithelial cells do not occur (Barnett et al., 2002). It is thus
possible that heparan sulphate proteoglycans, such as syndecans and glypicans,
concentrate GDNF to the vicinity of GFRα proteins and RET. A model, in which 
GDNF is locally concentrated by heparan sulphate proteoglycans is also supported
by the finding that very high concentrations of GDNF activate RET even in cells
depleted of surface heparin sulphates (Barnett et al., 2002). Furthermore, heparan
sulphate is required for the development of renal collecting ducts in vivo and in
culture (Davies et al., 1995; Bullock et al., 1998). Mice lacking heparan sulphate 2-
sulfotransferase, which is an essential enzyme in the synthesis of heparan
sulphates, lack kidneys (Bullock et al., 1998). In these mice, the ureteric bud is
unable to undergo branching morphogenesis, which is a GDNF-dependent process
(Bullock et al., 1998; reviewed by Sariola and Saarma, 2003).
1.1.4 RET-independent GDNF/GFRα1 signaling
GDNF can signal independently of RET through GFRα1, as suggested by the 
widespread expression of GFRα in many areas of the nervous system without co-
expression of RET (Trupp et al., 1997; Ylikoski et al., 1998; Kokaia et al., 1999).
In RET-deficient cell lines and primary neurons, GDNF triggers Src-family kinase
activation and phosphorylation of MAP kinase, PLC-, CREB, and induction of
Fos (Poteryaev et al., 1999; Trupp et al., 1999). These findings suggest that GFLs
may signal in neuronal and glial cells independently of RET in collaboration with
other transmembrane protein(s). Neural cell adhesion molecule (NCAM) has been
recently found to function as an alternative signalling receptor for GFLs (Paratcha
et al., 2003). In the absence of GFRα proteins, GFLs interact with NCAM with low 
afinity. When GFRα1 is associated with NCAM, GDNF binds with high affinity to 
p140NCAM and activates in the cytoplasm the Src-like kinase Fyn and the focal
adhesion kinase FAK (Fig. 4). Association of GFRα1 with NCAM also inhibits 
NCAM-mediated cell adhesion if GDNF is not present (Paratcha et al., 2003). The
ability of GFRα1 to modulate NCAM-mediated cell adhesion in the absence of
GDNF suggests independent roles for GFRα1-NCAM and GDNF-GFRα1-NCAM
signalling. By binding to NCAM, GDNF stimulates Schwann cell migration and
axonal growth in hippocampal and cortical neurons in a RET-independent fashion.
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These findings suggest that GFRα proteins and GFLs, interacting either together or
alone with NCAM, use different signalling pathways to modulate both short- and
long-range intercellular communication (Paratcha et al., 2003; Sariola and Saarma,
2003). A recent study demonstrating that both in vitro and in vivo effects of GDNF
on midbrain dopaminergic neurons are inhibited by an NCAM blocking antibody
further supports the physiological relevance of GDNF signalling through NCAM
(Chao et al., 2003).
Figure 4. Non-RET signalling for GDNF. NCAM is an alternative signalling
receptor for GFLs. It interacts with a GDNF-GFR1 dimer leading to activation of
Fyn, a Src-like kinase. Association of GFRα1 with NCAM inhibits NCAM-
mediated cell adhesion if GDNF is not present. Proteins are not drawn to scale.
(Modified from Sariola and Saarma, 2003).
1.1.5 Activation of RET by other growth factors
Early studies demonstrated that nerve growth factor (NGF) is the classical trophic
factor acting on sympathetic superior cervical ganglion (SCG) neurons. During
embryonic development, the survival of almost all SCG neurons depends on NGF
and its receptor NTRK1 (also known as TrkA). Evidence indicating that GDNF,
NRTN, and ARTN also act on SCG neurons has accumulated during recent years
(reviewed by Airaksinen and Saarma, 2002; Sariola and Saarma, 2003). Activation
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of the tyrosine kinase receptor NTRK1 by NGF is not needed for the survival of the
postnatal sympathetic neurons, but it is required for their growth and for
development of a mature neurotransmitter phenotype. Although the level of RET
phosphorylation increases with postnatal age in sympathetic neurons in vitro and in
vivo, its function in these neurons during postnatal development remains unclear.
Unexpectedly, NGF promotes the phosphorylation of the long isoform of RET
independently of either GFLs or GFRα co-receptors (Tsui-Pierchala et al., 2002c).
NGF promotes RET51 phosphorylation through a novel GFL-independent inter-
receptor-tyrosine-kinase signalling mechanism, yielding enhanced growth,
metabolism and gene expression. Since NGF activates only RET51
phosphorylation and not that of the short isoform RET9, it is unlikely that NGF
would simply modulate the levels of GDNF protein. These results show how
growth factors and their receptors engage in cross-talk to form a network of inter-
related trophic signals that guide development. The molecular mechanism of this
cross-talk between NTRK1 and RET is unknown, but is apparently indirect
(Sariola and Saarma, 2003).
1.1.6 Role of RET signalling during development
RET signalling has a critical role in the development of the enteric nervous system
(ENS) and kidney, as attested by the similar phenotype of mice deficient for
GDNF, RET or GFRα1. They al show severe defects in enteric innervation and 
renal differentiation (Moore et al., 1996; Pichel et al., 1996; Schuchardt et al.,
1994, 1996; Cacalano et al., 1998; Enomoto et al., 1998; Taraviras et al., 1999). A
loss of certain cranial parasympathetic ganglia (otic and sphenopalatine) of the
newborn Ret-, Gdnf- and Gfrα1-mutants indicates that GDNF/RET signalling has a
role in the early development of the parasympathetic nervous system (PNS)
(Marcos and Pachnis, 1996; Enomoto et al., 2000; Rossi et al., 2000). During
vertebrate embryogenesis Ret is expressed in the developing excretory system, in
all lineages of PNS and widely in many central nervous system nuclei, including
motor and catecholaminergic neurons (Pachnis et al., 1993; Avantaggiato et al.,
1994; Tsuzuki et al., 1995; Durbec et al., 1996b). In adult tissues Ret remains
expressed in peripheral enteric, sympathetic and sensory neurons as well as widely
in several brain regions including central motor, dopamine and noradrenaline
neurons (Pachnis et al., 1993; Avantaggiato et al., 1994; Tsuzuki et al., 1995;
Durbec et al., 1996b; Trupp et al., 1997; Young et al., 1998; Bennet et al., 1998).
The development of the metanephric kidney is initiated by the reciprocal
interaction of nephrogenic mesenchyme and the Wolffian duct-derived ureteric bud
(Saxén and Sariola, 1987; reviewed by Cho and Dressler, 2003; Sariola et al.,
2003). The ureteric bud induces epithelial differentiation of the nephrogenic
mesenchyme, which in turn promotes branching of the bud. Gdnf is expressed by
the nephrogenic mesenchyme and Ret by the tips of the adjacent branching ureteric
bud (Hellmich et al., 1996; Suvanto et al., 1996). Gfrα1is expressed by both the
nephrogenic mesenchyme and the ureteric bud (Sainio et al., 1997). Metanephric
development is initiated in 61% of Ret-deficient embryos (Schuchardt et al., 1994),
which suggests that also other, non-RET signalling systems are involved in ureteric
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branching (Sariola and Saarma, 2003). In contrast to the normal expression only at
the bud tips, the misexpression of Ret throughout the ureteric bud branches causes
variable inhibition of ureteric bud growth (Srinivas et al., 1999). Moreover,
expression of Hox7/Ret-PTC2 transgene, encoding a ligand-independent form of
RET, causes the development of abnormal nodules, outside the kidney or at its
periphery, containing branched epithelial tubules apparently formed by deregulated
growth of the ureteric bud. This suggests that RET signalling is not only necessary
but is sufficient to induce ureteric bud growth, and that the orderly, centripetal
growth of the bud tips is controlled by the spatially and temporally regulated
expression of GDNF and RET (Srinivas et al., 1999). The mice lacking GDNF
show a more severe renal phenotype than Ret- or GFRα1-deficient mice (Pichel et
al., 1996). However, tissue culture studies have further implied that, although
GDNF is essential for ureteric bud branching, other mesenchyme-derived signals,
possibly pleiotrophin/heparin-binding growth-associated molecule (HB-GAM), are
required (Sainio et al., 1997; Qiao et al., 1999). However, HB-GAM knock-out
mice mice have normal kidneys (Pavlov et al., 2002). Heparan sulphate
proteoglycans may have a role for GDNF/RET signalling in embryonic kidneys,
because the effect of depriving kidneys of heparin sulphates is similar to that of
knocking out Gdnf or Ret (Bullock et al., 1998). NRTN, Gfrα2and NCAM are also
expressed in the developing kidney, but they have no renal phenotype when
knocked out (Heuckeroth et al., 1999; Rossi et al., 1999; Cremer et al., 1994).
Therefore, their in vivo roles in renal differentiation remain unclear (Sariola and
Saarma, 2003).
In the testis, Gdnf is expressed by Sertoli cells that regulate spermatogenesis
in a paracrine manner. Ret and Gfrα1are displayed by a subset of undifferentiated
spermatogonia, including the spermatogenic stem cells (Meng et al., 2000). Gene-
targeted mice that have one Gdnf-null allele show partial depletion of
spermatogenic stem cells, whereas mice overexpressing GDNF show clusters of
undifferentiated spermatogonia. GDNF, but not NRTN, contributes to the paracrine
regulation of spermatogonial self-renewal and differentiation (Meng et al., 2000;
Meng et al., 2001). Reduced dosage of GDNF in Gdnf +/- mice leads to excess
differentiation of spermatogonia, depletion of the stem cells and finally to Sertoli-
cell-only histology. An increased dosage of GDNF allows undifferentiated
spermatogonia to self-renew but not differentiate. Mice expressing a dominant-
negative RET show defective spermatogenesis due to a decreased number of germ
cells and degeneration of seminiferous tubules, supporting a crucial role for RET in
early spermatogenesis (Jain et al., 2004a).
1.2 RET INTERACTING PROTEINS
RET activates several intracellular signalling cascades, which regulate cell
survival, differentiation, proliferation, migration, chemotaxis, branching
morphogenesis, neurite outgrowth and synaptic plasticity. Since, for a long time,
RET was an orphan receptor tyrosine kinase, extensive studies on RET signalling
have been performed using chimeric and/or oncogenic forms of RET.
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Ligand stimulated RET, as well as constitutively active oncogenic RET
proteins, are phosphorylated at specific cytoplasmic tyrosine residues (Liu et al.,
1996; Xing et al., 1998; Coulpier et al., 2002). Tyrosine autophosphorylation is
required for RET signalling. The intracellular domain of RET contains at least 12
autophosphorylation sites (Liu et al., 1996; Salvatore et al., 2000; Coulpier et al.,
2002; Kawamoto et al., 2004). Sites Tyr1090 and Tyr1096 are present only in the
RET51 isoform. Interactions of RET with a variety of downstream targets have
been identified (Fig. 5).
Phosphorylated tyrosine residues Tyr905, Tyr981, Tyr1015, and Tyr1096
have been identified as docking sites for Grb7/Grb10, Src, phospholipase C-
(PLC-), and Grb2, respectively (Pandey et al., 1995, 1996; Encinas et al., 2004;
Borrello et al., 1996; Alberti et al., 1998). Phosphorylation of Tyr905 stabilises the
active conformation of the kinase and facilitates the autophosphorylation of
tyrosine residues mainly located in the C-terminal tail (Iwashita et al., 1996a).
Tyr1062 acts as a docking site for many adaptor or effector proteins: Shc, ShcC,
FRS2, IRS1/2, Dok1, Dok4/5, Dok6, Enigma, and PKC(Asai et al., 1996; Durick
et al., 1996; Arighi et al., 1997; Lorenzo et al., 1997; Ohiwa et al., 1997; Hennige
et al., 2000; Kurokawa et al., 2001; Melillo et al., 2001a; Melillo et al., 2001b;
Grimm et al., 2001; Murakami et al., 2002; Pelicci et al., 2002; Andreozzi et al.,
2003; Crowder et al., 2004). Upon ligand stimulation, at least two distinct protein
complexes assemble on phosphorylated Tyr1062 via Shc, one leading to activation
of the Ras/ERK pathway through recruitment of Grb2/Sos and another to the
PI3K/Akt pathway through recruitment of Grb2/GAB. This latter complex can also
assemble directly onto phosphorylated Tyr1096, offering an alternative route to
PI3K activation by GDNF (Besset et al., 2000; Hayashi et al., 2000). The Ras/ERK
and PI3K pathways via Tyr1062 are important for activation of CREB and NFB
transcription factors, respectively (Hayashi et al., 2000). Big mitogen-activated
protein kinase 1 (BMK1) is also activated via Tyr1062 (Hayashi et al., 2001). The
signalling via Tyr1062 plays a crucial role in the migration and/or proliferation of
ENS progenitors and it is required for ureteric bud branching at later stages of
nephrogenesis (Jijiwa et al., 2004). The binding of Shc, FRS2, IRS1/2, and Dok
proteins to Tyr1062 is dependent on phosphorylation of this residue and it is
mediated by PTB or SH2 phosphotyrosine binding domains. In contrast, the
binding to Tyr1062 of Enigma, a member of the PDZ-LIM family, is
phosphorylation-independent. Furthermore, Enigma binds specifically RET9, since
short isoform-specific amino acid residues +2 to +4 to Tyr1062 are required for
interaction with Enigma (Borrello et al., 2002).
In most cases tyrosine residues Tyr905, Tyr1015, Tyr1062 and Tyr1096 of
RET are phosphorylated, but after the elevation of cyclic AMP (cAMP) levels,
Ser696 is also phosphorylated. Protein kinase A (PKA)-dependent Ser696
phosphorylation is important for GDNF/RET-induced Rac activation and
lamellipodia formation (Fukuda et al., 2002), indicating that cytoskeletal
rearrangement by the activation of RET is controlled probably by a cAMP-
dependent mechanism via serine phosphorylation. The role in RET signalling of
additional tyrosine residues that are phosphorylated upon GFLs binding (Tyr687,
Tyr826 and Tyr1029) remains unclear. Tyr752 and Tyr928 in the constitutive
active RET serve as docking sites for STAT3 (Schuringa et al., 2001). The
phosphoinositide-dependent kinase 1 (PDK1) and STAT1 are phosphorylated and
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activated by oncogenic RET/PTC (Kim et al., 2003; Hwang et al., 2004); however
the critical residues of RET for their activation have to be identified.
1.2.1 Downstream signalling pathways
RET activates several pathways typical of receptor tyrosine kinase signalling.
These include the Ras/RAF pathway, which leads to activation of the mitogen-
activated protein kinases ERK1 and ERK2 (Santoro et al., 1994; van Weering et
al., 1995; Worby et al., 1996; Trupp et al., 1999), phosphatidylinositol 3-kinase
(PI3K), resulting in activation of the serine-threonine kinase Akt and cell survival
(van Weering and Bos, 1997; Trupp et al., 1999; Segouffin-Cariou and Billaud,
2000; Maeda et al., 2004), Jun NH2-terminal protein kinase (JNK) (Chiariello et
al., 1998), p38MAPK (Kurokawa et al., 2003), ERK5 (Hayashi et al., 2001) and
PLC-(Borrello et al., 1996). The Ras/MAP kinase pathway appears to contribute
to neuronal survival and neurite outgrowth in the nervous system (Creedon et al.,
1997; van Weering et al., 1997) and to ureteric branching during nephrogenesis
(Fisher et al., 2001). PI3K signalling (possibly independent of its downstream
substrate, the Ser/Thr-kinase Akt) is required for GDNF-induced formation of large
lamellipodia, which are implicated in neuritogenesis (van Weering et al., 1997; van
Weering et al., 1998; Maeda et al., 2004) and differentiation of cultured dopamine
neurons (Pong et al., 1998). RET can activate the JNK pathway via Rho/Rac-
related small GTPases, such as Cdc42 (Chiariello et al., 1998). Both PI3K/Akt and
JNK pathways are key regulators of neurotrophin-dependent neuronal survival
(reviewed by Kaplan and Miller, 2000), suggesting that they may also play roles in
mediating the trophic effects generated by RET signalling. Abrogation of PLC--
dependent signalling blocks the oncogenic activity of RET (Borrello et al., 1996).
The PLC-pathway regulates the intracellular level of Ca2+ ions by increasing the
level of inositol (1,4,5)-trisphosphate. Changes in intracellular free Ca2+
concentration are important in the action of neurotrophic factors by activating
many signal transduction cascades, for example, those that regulate gene
expression (reviewed by Finkbeiner and Greenberg, 1998).
Although many of the pathways through which RET transduces signals
have been identified, little is known of the target genes that are specifically
modulated in response to receptor activation (Watanabe et al., 2002; Jain et al.,
2004b). Gene expression analysis of embryonic kidney-derived cell lines
expressing RET9 or RET51 showed up-regulation of stress response genes, besides
the predictable altered expression of genes involved in cell-cell interaction, cell
proliferation, and neuroendocrine differentiation (Myers and Mulligan, 2004).
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Figure 5. Schematic illustration of the intracellular signalling transducers
interacting with activated RET. Dotted lines indicate that the interaction is likely
indirect. Arrows do not implicate direct interactions but the deduced or presumed
order of different signalling components. Enigma binding to Tyr1062 is
phosphorylation independent. PKCactivation negatively modulates RET kinase.
1.2.2 Shc family adaptor proteins
Signal transduction initiated by a wide variety of extracellular signals involves the
activation of receptor protein tyrosine kinases. Phosphorylated tyrosine residues in
activated receptors or docking proteins then function as binding sites for the Src
homology 2 (SH2) or phosphotyrosine-binding (PTB) domains of cytoplasmic
signalling proteins. The adaptor protein Shc was initially identified as an SH2
containing proto-oncogene involved in growth factor signalling (Pelicci et al.,
1992). Shc genes are present in all multicellular organisms analysed to date from
nematodes to human (Luzi et al., 2000). Three mammalian Shc genes have been
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identified and their gene products have been referred to as ShcA, ShcB, and ShcC
(O’Bryan et al., 1996; Pelicci et al., 1996).
In mammals ShcA is ubiquitously expressed, while expression of the other
two Shc-related genes is either exclusively (ShcC) or predominantly (ShcB)
restricted to the nervous system (Nakamura et al., 1996; O’Bryan et al., 1996;
Pelicci et al., 1996). Due to alternative initiation and splicing patterns, these three
genes encode at least six proteins (p66Shc, p52Shc, p46Shc, p64Rai, p52Rai, and
p68Sli), all of which contain a unique PTB-CH1-SH2 modular organisation. PTB
and SH2 are phosphotyrosine-binding domains that are found in numerous
different proteins, but the concomitant presence of the PTB and SH2 domains (in
the order N-PTB-SH2-C) is unique to the proteins of the Shc family (Luzi et al.,
2000). The Shc-SH2 domain has a characteristic pocket for binding of
phosphotyrosine (pTyr), and the specificity of binding depends on residues C-
terminal to the pTyr. In contrast, the Shc-PTB binding to target sequences is
determined by residues N-terminal to the pTyr (reviewed by Ravichandran, 2001).
Moreover, the Shc-PTB domain is structurally similar to the pleckstrin homology
(PH) domains and binds acidic phospholipids such as PI(4,5)P2 and PI(3,4,5)P3
(Zhou et al., 1995; Rameh et al., 1997), allowing membrane localisation of Shc
independently of the interaction with tyrosine-phosphorylated receptors
(Ravichandran et al., 1997). Residues within Shc-PTB critical for phospholipid
binding (and in turn, membrane localisation) are distinct from the residues
necessary for pTyr binding (and in turn, receptor binding).
The modular organisation of the proteins of the Shc family suggests that
they function as adaptors within cytoplasmic signalling pathways. P52/46Shc
proteins are rapidly and efficiently tyrosine-phosphorylated by cell surface
receptors for growth factors (Pelicci et al., 1992, 1995; Segatto et al., 1993; Pronk
et al., 1994; Sasaoka et al., 1994; Stephens et al., 1994; Yokote et al., 1994;
Giorgetti et al., 1994; Vainikka et al., 1994; Borrello et al., 1994; Gelderloos et al.,
1998), antigens, cytokines, hormones and coupled to G-proteins (reviewed by
Ravichandran, 2001). In addition, a role for Shc has been ascribed in
transformation by the polyoma middle T antigen and BCR-ABL oncoprotein.
Moreover, hyper-phosphorylation of Shc has been seen in many different types of
tumors (reviewed by Ravichandran, 2001). The importance of Shc in vivo has been
demonstrated by ShcA-deficient mice, which show embryonic lethality at day 11.5
with severe defects in heart development and establishment of mature blood vessels
(Lai and Pawson, 2000). Null mutations of ShcB and ShcC in mice resulted in no
overt neuroanatomical abnormalities within the central nervous system. However,
analysis of sympathetic and sensory neuronal populations revealed loss of
sympathetic neurons in the mice lacking both ShcB and ShcC (but not in the single-
null mutants) as well as loss of nociceptive sensory neurons in the ShcB mice
(Sakai et al., 2000), indicating that these Shc family members possess both unique
and overlapping functions in neural development. Three major Shc
phosphorylation sites (tyrosine residues 239, 240 and 317) have been identified
within its proline- and glycine-rich CH1 region (Salcini et al., 1994; van der Geer
et al., 1996a). Once phosphorylated, the p52/46Shc proteins act to bridge receptor
tyrosine kinases and the Grb2 adaptor proteins (Bonfini et al., 1996). Grb2, in turn,
is constitutively complexed to Sos, a Ras guanine nucleotide exchange factor
(Chardin et al., 1993). Recruitment of the Grb2/Sos complex by p52/46Shc results
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in the membrane relocalisation of Sos, an event sufficient to induce Ras-MAPK
activation (Rozakis-Adcock et al., 1992). ShcA can also associate, either directly or
via Grb2, with the docking protein Gab1 that in turn binds PI3-kinase (Ingham et
al., 1998). Additional ShcA partners have been described, including SH3-
containing proteins and adaptins (Weng et al., 1994; Matoskova et al., 1995;
Okabayashi et al., 1996). ShcC is not a common substrate of receptor tyrosine
kinases under physiological conditions and among the receptors RET, EGF, and
NTRK1, it is activated specifically by RET (Pelicci et al., 2002). ShcC exerts a
pro-survival function in neuronal cells by coupling RET to the PI3K/Akt signalling
pathway.
Shc proteins may also have functions other than leading to the activation of
signalling pathways. Homozygous inactivation of p66Shc in mice extends their life
spans and increases cellular resistance to oxidative stress-induced apoptosis
(Migliaccio et al., 1999). p66Shc is not involved in Ras activation (Migliaccio et
al., 1997) and it is implicated in pathways activated by environmental stress
(Migliaccio et al., 1999). Interestingly, p66Shc contains a second CH-like domain
(denoted as CH2) (Migliaccio et al., 1997). The CH2 domain is not tyrosine
phosphorylated, but instead becomes serine phosphorylated. This serine
phosphorylation has been linked to the role of p66Shc isoform in oxidative stress
response.
1.3 RET ACTIVATION IN HUMAN CANCER
1.3.1 RET in papillary carcinomas of the thyroid gland
Thyroid tumors are the most prevalent malignancies of the endocrine system.
Follicular-cell-derived tumors are comprised of benign adenomas, well
differentiated (papillary or follicular), poorly differentiated (insular), and
undifferentiated (anaplastic) carcinomas. Papillary thyroid carcinoma (PTC) is the
most common thyroid carcinoma. It is defined on the basis of the histological
pattern and/or distinctive nuclear features, i.e., ground glass appearance and
longitudinal grooves with cytoplasm invaginations (Hedinger et al., 1988; Rosai et
al., 1992). PTC is subclassified according to morphological features into classic,
follicular, solid, diffuse/sclerosing, tall-cell, columnar-cell, and diffuse/follicular
variants. The tall-cell, solid, diffuse/sclerosing, and diffuse/follicular variants are
associated with a higher incidence of local and vascular invasion and of regional
and distant metastases (Hedinger et al., 1989; Rosai et al., 1992).
Somatic chromosomal rearrangements involving the RET gene represent the
most frequent genetic alteration in PTC, although wide variations of frequency,
ranging from 5 to 70%, have been observed among different geographic areas
(reviewed by Pierotti et al., 1996; Jhiang, 2000). These rearrangements lead to the
fusion of the RET tyrosine kinase domain to the 5-terminal regions of
heterologous genes, generating chimeric oncogenes designated as RET/PTC. To
date, ten rearranged forms of RET referred to as RET/PTC 1-8, RET/PCM1, and
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ELKS/RET have been isolated from sporadic and radiation-associated PTCs (Fig.
6) (Alberti et al., 2003; Ichihara et al., 2004). In each case, the intracellular domain
of RET is fused to different activating genes, namely H4 (for RET/PTC1), RI
(RET/PTC2), RFG/ELE 1/ARA70 (RET/PTC3 and RET/PTC4), RFG 5
(RET/PTC5), hTIF (RET/PTC6), RFG 7/TF1(RET/PTC7), kinectin (RET/PTC8),
PCM1 (RET/PCM1), and ELKS (ELKS/RET), resulting in the ligand-independent
dimerisation and constitutive activation of these chimeric proteins. RET, H4, and
RFG genes map on the long arm of chromosome 10, and their fusion is generated
by chromosome inversions; RET/PTC2 is generated by a reciprocal balanced
translocation between chromosomes 10 and 17 (Fig. 6). When RET/PTC1 or
RET/PTC3 are targeted to the thyroid in transgenic mice, they develop thyroid
tumors resembling human PTC, proving that RET/PTC oncogenes are able to
initiate thyroid carcinogenesis (Santoro et al., 1996; Jhiang et al., 1996; Powell et
al., 1998; Buckwalter et al., 2002).
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Figure 6. Mechanisms of chromosomal rearrangements generating transforming fusion genes
resulting in fusion gene products. RET/PTC oncogenes, which are found in papillary thyroid
carcinomas, are chimeric genes generated by chromosomal rearrangements that lead to the fusion of
the RET tyrosine kinase domain to different heterologous genes. Arrows indicate breakpoints in
papillary thyroid cancer. SP, signal peptide; TM, transmembrane domain; TK, tyrosine kinase
domain; CC, coiled-coil domain. (Modified from Santoro et al., 2002a).
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RET/PTC rearrangements activate the transforming potential of RET by
multiple mechanisms (Santoro et al., 2002a). First, by substituting its
transcriptional promoter with those of the fusion partners, they allow the
expression of RET in the epithelial follicular thyroid cells, where it is normally
transcriptionally silent. Secondly, the rearrangements generate constitutively active
chimeric oncoproteins, which are distributed in the cytosolic compartment of the
cell. Finally, activation of the RET kinase is mediated by fusion to domains that are
capable of dimerisation.
Ionising radiation can induce RET/PTC rearrangements, and thyroid cancer
is the most common solid neoplasm associated with radiation exposure (Williams,
1993). Accordingly, a dramatic increase in the incidence of pediatric papillary
carcinoma was reported after the Chernobyl nuclear accident of April 26, 1986
(Jacob et al., 1998). Intrachromosomal rearrangements involving RET and the
adjacent H4 (RET/PTC1) or RFG/ELE 1 (RET/PTC3) have been found in 57% of
thyroid cancers of children from contaminated areas (Ito et al., 1994; Fugazzola et
al., 1995; Klugbauer et al., 1995; Nikiforov et al., 1997). RET/PT3 rearrangement
is strongly associated also with PTC of short latency and connected with the solid-
follicular variant (Thomas et al., 1999). Transgenic mice expressing RET/PTC3 in
the thyroid display an aggressive tumor phenotype, including lymph node
metastases (Powell et al., 1998). In contrast, RET/PTC1 transgenic mice develop
follicular hyperplasia and carcinoma, but not invasive cancer (Santoro et al., 1996).
Recently, the RET/PTC3 rearrangement has been shown to have more potent
mitogenicity than RET/PTC1. The high oncogenic potential of RET/PTC3
correlates with its prevalence in the aggressive tall-cell variant (TCV) of PTCs
(Basolo et al., 2002). These findings support a model whereby the correlation
between the RET/PTC rearrangement and the aggressiveness of human PTC is
related to the efficiency with which the oncogene subtype delivers mitogenic
signals to thyroid cells (Basolo et al., 2002).
Regulation of the cyclin-dependent kinase inhibitor p27kip1 contributes to
mitogenic effects of RET/PTC in human thyroid carcinoma cell lines naturally
harboring RET/PTC1 (Vitagliano et al., 2004). The up-regulation of p27kip1 level
also represents a molecular mechanism whereby activated RET regulates the
growth and terminal differentiation of cells that differentiate along the neuronal
pathway (Baldassarre et al., 2002). Furthermore, RET/PTCs are able to induce the
expression of the CXCR4 chemokine receptor (Castellone et al., 2004a) and of
osteopontin (OPN) and its receptor CD44 (Castellone et al., 2004b). OPN is a
highly acidic calcium-binding glycosylated phosphoprotein and it is also regarded
as a cytokine (Ashkar et al., 2000; Chabas et al., 2001). CXCR4 and OPN up-
regulation is implicated in the mitogenic, motile, and invasive phenotype of
RET/PTC transformed thyroid epithelial cells. Thus, chemokines and their
receptors might play a role in promoting malignant progression of thyroid cancers
bearing RET/PTC rearrangements. RET/PTC has been shown to transmit not only
mitogenic but also proapoptotic signals to thyroid cells (Castellone et al., 2003).
A high frequency of RET rearrangements has been found in occult PTCs
(Viglietto et al., 1995) and papillary microcarcinomas, which are papillary tumors
with low growth and invasion tendency (Tallini et al., 1998; Nasir et al., 2000,
Corvi et al., 2001a), indicating that RET/PTC activation represents an early event
in the process of thyroid cell transformation. Moreover, 10% of poorly
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differentiated thyroid carcinomas (PDCs) exhibit evidence consistent with
RET/PTC activation. The percentage increases to about 20% if only PDCs with
histologic changes indicating evolution from a well differentiated PTC are
considered (Santoro et al., 2002b). These data suggest that PDC may result from
dedifferentiation of PTC but do not support a major role for RET/PTC in this
process nor do they support a significant role for RET/PTC with PDC-associated
poor prognosis.
RET/PTC has been also reported in non-invasive thyroid nodules that
exhibit borderline morphological signs of papillary cancer (Fusco et al., 2002).
RET activation closely parallels the morphological changes in these nodules where
it is restricted to those areas of the tumor exhibiting the cytological alterations of
papillary carcinoma, raising the possibility that such foci may precede the
development of invasive papillary cancer. Interestingly, other recent studies
support a discordance between RET rearrangement status and papillary thyroid
carcinoma-like morphology in thyroid tumors. For example, up to 50% of Hürthle
cell thyroid tumors harbor RET rearrangements (Chiappetta et al., 2002; Cheung et
al., 2000a), despite the view that they are more closely related to follicular tumors
than to papillary carcinoma. RET rearrangements are also present in hyalinizing
trabecular tumors of the thyroid (Papotti et al., 2000; Cheung et al., 2000b). In
addition, papillary carcinomas containing RET/PTC3 rearrangement have been
shown to exhibit a spectrum of histologies (classic, solid, and tall cell) that have
different biological tendencies (Nikiforov et al., 1997; Thomas et al., 1999; Basolo
et al., 2002). Thyroid tumors with mixed morphological and clinical features of
papillary and follicular carcinoma have also been described (Baloch and LiVolsi,
2000). These findings suggest that there is an imprecision in the morphological
categorisation of thyroid tumors and that unknown cellular factors cooperate with
RET rearrangement to determine papillary carcinoma morphology and biology. It is
likely that molecular endocrine tumor markers will help to subdivide thyroid and
other endocrine tumors into more distinct biological subgroups (Kroll, 2002).
RET rearrangements in familial papillary thyroid carcinomas (FPTCs) have
been reported (Corvi et al., 2001b). Nevertheless, no linkage to RET has been
found in these tumors (Lesueur et al., 1999), suggesting that RET is not involved in
the predisposition to FPTC and that other genes may be responsible for the
development of this tumor.
RET/PTC rearrangements have been observed also in non-neoplastic
Hashimoto’s thyroiditis (Sheils et al., 2000). Interestingly, recent clinical
observations showed that the phenotypes of PTC and Hashimoto’s thyroiditis are 
closely related in terms of their histology and immunohistochemical staining
patterns, and more importantly, share the same molecular profile (Di Pasquale et
al., 2001; Arif et al., 2002). Hashimoto’s thyroiditis is also associated with 
submicroscopic foci of papillary thyroid cancer (Fink et al., 1996). These
observations suggest that RET/PTC activation may play a role in thyroid-specific
autoimmune responses and raises therapeutic challenges of patients with
Hashimoto’s thyroiditis.
30
1.3.2 Other genes activated in papillary thyroid carcinomas (PTCs)
NTRK1 is the other RTK activated in PTCs, although with a lower frequency
compared to RET (Pierotti et al., 1995). Like RET, the activation of NTRK1 is
caused by chromosomal rearrangements, leading to the fusion of the 3end of
NTRK1 gene to the 5end of three different genes, forming four chimeric gene
variants. The NTRK1 gene joins to TPM3 (Martin-Zanca et al., 1986), TPR (Greco
et al., 1992) or TFG (Greco et al., 1995), generating chimeric genes designated
TRK, TRK-T1, TRK-T2, and TRK-T3, respectively. TRK-T1 and TRK-T2 are two
fusion variants of TPR-NTRK1 rearrangement (Greco et al., 1997). Differently
from the RET oncogenes, all known TRK oncogenes, except TRK-T1, also contain
the NTRK1 transmembrane domain.
Other frequent genetic events in PTCs are activating point mutations of the
BRAF serine-threonine kinase (Kimura et al., 2003; Namba et al., 2003). Sporadic
papillary carcinomas preferentially harbor BRAF mutations rather than RET/PTC
rearrangements, whereas radiation-induced tumors demonstrate a low prevalence
(4%) of BRAF point mutations and high prevalence (58%) of RET/PTC
rearrangements, suggesting a significant difference in the molecular genetic profile
of sporadic and radiation-induced thyroid tumors (Nikiforova et al., 2004; Lima et
al., 2004). The Val599Glu BRAF mutation is significantly associated with the PTC
tall cell variant (Frattini et al., 2004). Gene expression profiling using cDNA
microarray chips suggests that the BRAF mutation and RET/NTRK1 rearrangements
are associated with similar but distinct gene expression patterns in papillary thyroid
cancer (Frattini et al., 2004).
The occurrence of activating RAS mutations, commonly found in follicular
thyroid neoplasms, is controversial in PTC, since some authors reported their
prevalence varying between 6 and 45%, whereas other studies failed to identify any
mutation (Namba et al., 1990; Esapa et al., 1999). Interestingly, RET, RAS and
BRAF signal through the same pathways in thyroid cells, and their mutations are
mutually exclusive in human PTC samples (Kimura et al., 2003; Frattini et al.,
2004).
1.3.3 Medullary thyroid carcinoma
Medullary thyroid carcinoma (MTC) is a malignant tumor arising from calcitonin
(CT)-secreting parafollicular C cells. MTC occurs sporadically (75% of cases) or
as a component of the familial cancer syndrome, multiple endocrine neoplasia type
2 (MEN 2) (25% of cases) (reviewed by DeLellis, 1995; Goodfellow and Wells,
1995; Sherman, 2003). MEN 2 is divided into three different clinical variants:
MEN 2A, MEN 2B, and familial medullary thyroid carcinoma (FMTC), all
inherited by autosomal dominant fashion (Table 1) (Brandi et al., 2001). MEN 2
vary in aggressiveness of MTC and the spectrum of affected organs. A common
feature is the thyroidal C cell hyperplasia before the occurrence of MTC. MTC that
occurs in hereditary forms is usually multifocal and bilateral. MEN type 2A is
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characterised by MTC, pheochromocytoma in about 50% of cases, and parathyroid
hyperplasia or adenoma in about 20-30% of cases. MEN 2A accounts for over 75%
of MEN 2 (Eng et al., 1996a). MEN 2B is the most distinctive and aggressive of
the MEN 2 variants and it is characterised by an earlier age of MTC onset
associated with pheochromocytoma (about 50% of cases) and more rarely by
developmental abnormalities which include mucosal neuromas, intestinal
ganglioneuromatosis, ocular and skeletal abnormalities (the so-called marfanoid
habitus). FMTC is characterised by the presence of MTC alone in at least four
family members. FMTC is considered the least aggressive of the three MEN 2
subtypes. Rare variants of MEN 2 include MEN 2A with cutaneous lichen
amyloidosis (Nunziata et al., 1989; Donovan et al., 1989) and MEN 2A or FMTC
with Hirschsprung’s disease (Verdy et al., 1982; Mulligan et al., 1994; Decker et
al., 1998).
Disease Characteristic features
MEN 2A
Thyroid C cells tumor
Pheochromocytoma
Parathyroid hyperplasia/adenoma
FMTC Thyroid C cells tumor
MEN 2A with
cutaneous lichen
amyloidosis
MEN 2A and a pruritic cutaneous lesion over
the upper back
MEN 2A or
FMTC with
Hirschsprung’s 
disease
MEN 2A or FMTC with intestinal
aganglionosis
MEN 2B
Thyroid C cells tumor
Pheochromocytoma
Intestinal and mucosal ganglioneuromatosis
Ocular abnormalities
Marfanoid habitus
Table 1. MEN 2 and its clinical variants or syndromes.
1.3.4 RET in MEN 2 syndromes
In 1991, genetic linkage analyses mapped putative loci for MEN 2 syndrome to a
small interval on chromosome 10q11.2, and later the RET gene was identified as
the susceptibility gene for these syndromes (Online Mendelian Inheritance in Men
OMIM 171400) (Donis-Keller et al., 1993; Mulligan et al., 1993; Carlson et al.,
1994a; Eng et al., 1994; Hofstra et al., 1994). Unlike most other cancer syndromes,
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which are associated with inactivation of tumor suppressor or DNA mismatch
repair genes, MEN 2 arises as a result of activating mutations of the RET gene.
The activation of RET as a dominant transforming gene by germline
mutations of MEN 2 has been analysed in fibroblasts (Santoro et al., 1995; Borrello
et al., 1995; Asai et al., 1995) and in different transgenic models (Michiels et al.,
1997; Sweetser et al., 1999; Gestblom et al., 1999; Acton et al., 2000; Kawai et al.,
2000; Smith-Hicks et al., 2000; Reynolds et al., 2001; Rajan et al., 2001).
Germline point mutations of RET are responsible for all autosomal dominant MEN
2 cancer syndromes, MEN 2A, MEN 2B, and FMTC (reviewed by Pasini et al.,
1996). These RET mutations fall into two main groups: those affecting the
extracellular and those affecting the tyrosine kinase domain (Fig. 7).
MEN 2A mutations cause the substitution of extracellular cysteines at
codons 609, 611, 618, 620 (exon 10), 630 or 634 (exon 11) with several other
residues (Table 2). Most MEN 2A patients have a mutation of Cys634, which is
highly predictive of the development of pheochromocytoma and parathyroid
hyperplasia. Rarer duplication of 9 or 12 base pairs in the critical cysteine-rich
domain results in MEN 2A (Hoppner and Ritter, 1997; Hoppner et al., 1998). MEN
2A due to two de novo mutations on the same RET allele has also been reported
(Tessitore et al., 1999). In some patients with MEN 2A, duplication of the mutant
allele in trisomy 10 or loss of the wild-type RET allele occur in the MEN 2-
associated tumors. A “second hit” causing a dominant effect of the mutant RET
allele has been proposed as a possible mechanism for pheochromocytoma
tumorigenesis in patients with MEN 2 (Huang et al., 2000).
FMTC mutations are similar to those causing MEN 2A, but are more
homogeneously distributed among cysteines 609, 618, and 620. Mutations of
residues 768, 790, 791 (exon 13), 804, 844 (exon 14), or 891 (exon 15) of the RET
tyrosine kinase domain have also been found in FMTC patients. Recently, a
pheochromocytoma was described with a codon 891 mutation, indicating that
patients with this mutation have a predisposition for MEN 2A (Jimenez et al.,
2004). Other rare mutations have been reported, such as a 9-base pair duplication
(Pigny et al., 1999) and a point mutation at codon 533 (Da Silva et al., 2004) in
exon 8, both resulting in an additional cysteine, or mutations at codons 804 and 778
on the same RET allele, which are associated with both FMTC and prominent
corneal nerves (Kasprzak et al., 2001).
MEN 2B is caused by the highly specific Met918Thr (95%) or Ala883Phe
(<5%) mutations (Carlson et al., 1994a; Smith et al., 1997). The Met918Thr
substitution is frequently a de novo mutation located on the allele inherited from
the patient’s father (Carlson et al., 1994b). The Met918Thr substitution is also
found in sporadic medullary thyroid carcinomas (sMTC), with Met918Thr
mutation-positive tumors often displaying a more aggressive phenotype. Two
germline missense mutations have been reported at codons 804 and 806 in the same
RET allele in a patient who had clinical features characteristic of MEN 2B
(Miyauchi et al., 1999) (Table 2).
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Figure 7. Schematic diagram of the RET gene and RET protein showing the
location of MEN 2 mutations. The germline mutations identified in more than
95% of MEN 2 families are clustered in specific regions of RET: the cysteine-rich
domain mutations in exons 10 and 11, or the tyrosine kinase domain mutations in
exons 13-16.
All these point mutations of RET have a “gain of function” efect. 
Constitutive dimerisation is the molecular mechanism of the activation of RET
molecules carrying mutations affecting extracellular cysteines (Santoro et al., 1995;
Borrello et al., 1995; Asai et al., 1995). Although the three-dimensional structure
of the RET extracellular domain is still unknown, these cysteines likely form
intramolecular disulfide bonds in the wild-type receptor, and the mutation results in
an unpaired cysteine, which forms an activating intermolecular bridge (Fig. 8). In
addition, mutations at codons 609, 618, and 620 markedly decrease the cell surface
expression of RET (Carlomagno et al., 1997; Ito et al., 1997; Chappuis-Flament et
al., 1998). Low maturation efficiencies and different intensities in the induction of
the dimerisation may explain the phenotypes caused by mutations of the different
cysteines. Indeed, kinase and oncogenic activities of RET mutant proteins
associated with FMTC are lower than those of the classic MEN 2A proteins. No
data are yet available on the mechanisms of activation of FMTC mutations
occurring in RET tyrosine kinase domain. RET carrying mutations at codons 768,
804, or 891 display lower transforming capacity compared to RET with
substitutions at codons 634, 918, or 883 strongly associated with MEN 2A and
MEN 2B, respectively (Pasini et al., 1997; Iwashita et al., 1999). Computer
modelling has suggested that the Glu768Asp substitution modifies the kinase
activity of the receptor by altering the substrate specificity or the ATP-binding
capacity (Pasini et al., 1997).
MEN 2A/FMTC mutations
MEN 2B mutations
RET gene
5’ 3’
Exon 2 3 4 5 6 8 13 15 18 192017141271
RET protein
11 16
SP CAD CYS TM TK
RET51
RET9
9 10 21
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Figure 8. Mechanism of disulfide bond-linked RET dimerisation. Constitutive
dimerisation is the molecular mechanism of the activation of RET molecules
carrying mutations affecting extracellular cysteine residues. The mutation of a
cysteine residue to a non-cysteine residue in RET-MEN 2A leaves an unpaired
cysteine in RET-MEN 2A monomer to form an intermolecular disulfide bond with
another RET-MEN 2A monomer. This type of mutation mimics the effect of ligand
binding such that RET-MEN 2A is constitutively dimerised and activated.
Unphosphorylated (Y) and phosphorylated (Y*) tyrosine residues are indicated.
(Modified from Alberti et al., 2003).
MEN 2B mutations cause constitutive activation of the RET transforming
potential. However, in addition to “quantitative” changes of the basal kinase 
activity, the most frequent MEN 2B mutation (Met918Thr) has been proposed to
afect also the “quality” of RET-generated intracellular signals (Santoro et al.,
1995). The residue corresponding to methionine 918 is highly conserved in all
receptor tyrosine kinases, whereas cytoplasmic protein tyrosine kinases show a
threonine in that position (Marengere et al., 1994). This residue is predicted to alter
the substrate selection, as it maps in the pocket of the kinase involved in substrate
binding (Songyang et al., 1995; Pandit et al., 1996). The change in substrate
specificity can affect RET-mediated phosphorylation of intracellular proteins as
well as the pattern of RET autophosphorylation sites. Both possibilities have been
experimentally proven. The pattern of phosphorylated intracellular proteins differs
in RET-MEN 2B- and RET-MEN 2A-expressing cells (Santoro et al., 1995;
Murakami et al., 1999; Salvatore et al., 2001). Moreover, phosphopeptide mapping
and antibodies specific to RET autophosphorylation sites have shown that RET-
MEN 2B autophosphorylation sites differ from those of wild-type RET and of
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RET-MEN 2A (Santoro et al., 1995; Liu et al., 1996; Salvatore et al., 2001). The
molecular mechanisms by which the Met918Thr mutation alters RET function are
thus many fold. On the one hand, this mutation leads to ligand-independent
activation of the kinase without causing a constitutive dimerisation of the RET
molecules. On the other hand, the Met918Thr substitution modifies RET substrate
specificity. In addition, MEN 2B kinase activity can be further enhanced by the
ligand (Bongarzone et al., 1998), and this probably results in a stimulation that is
stronger than that caused by the MEN 2A mutation. The combinations of these
mechanisms of MEN 2B activation may thus explain why MEN 2B is the most
aggressive form of MEN 2.
It is not known how the Ala883Phe affects RET function. However, residue
883 is located in a subdomain of RET that defines substrate preference (Smith et
al., 1997), suggesting that the alteration of substrate specificity may be the
common etiologic thread that underlies the pathogenesis of MEN 2B. A mouse
model of MEN 2B where the corresponding mutation was introduced to the Ret
gene demonstrated that heterozygous mutant mice displayed several features of the
human disease, including C cell hyperplasia and chromaffin cell hyperplasia
progressing to pheochromocytoma, while homozygotes displayed more severe
thyroid and adrenal disease, ganglioneuromas of the adrenal medulla and
enlargement of the associated sympathetic ganglia and male infertility (Smith-
Hicks et al., 2000).
Studies using expression profiling may be instrumental in associating
expression fingerprints of tumor subtypes with specific genetic alterations and
tumor behavior. A differential display analysis of gene expression using NIH 3T3
cells expressing the RET-MEN 2A or RET-MEN 2B mutant proteins identified ten
genes induced by both mutant proteins and eight genes that were repressed
(Watanabe et al., 2002). The induced genes include cyclin D1, cathepsins B and L,
and cofilin that are known to be involved in cell growth, tumor progression, and
invasion. In contrast, the repressed genes include type I collagen, lysyl oxidase,
annexin I, and tissue inhibitor of matrix metalloproteinase 3 that have been
implicated in tumor suppression. In addition, six RET-MEN 2A-specific- and five
RET-MEN 2B-specific-inducible genes were identified. Among these genes,
stanniocalcin1 (STC1) expression has been suggested to play a role in the MEN 2B
phenotype. Expression microarray analysis of benign (pheochromocytomas) and
malignant (MTCs) tumors from patients with MEN 2A or MEN 2B revealed that
genes involved in the process of epithelial to mesenchymal transition are up-
regulated in MEN 2B MTCs (Jain et al., 2004b). This MEN 2B MTC profile may
explain the early onset of malignancy in MEN 2B compared to MEN 2A patients.
Furthermore, chondromodulin-1 was expressed at high levels specifically in MEN
2B MTCs. Both stanniocalcin1 and chondromodulin-1 play a role in bone
formation and provide molecular evidence associating skeletal abnormalities with
MEN 2B phenotype.
Recent studies have reported the presence of papillary thyroid carcinoma in
patients affected by FMTC carrying germline point mutations in RET at codons
603 (Rey et al., 2001), 634 (Melillo et al., 2004), 790, 791, 804 (Feldman et al.,
2000; Brauckhoff et al., 2002; Papi et al., 2003), and 918 (Orlandi et al., 2001).
Furthermore, one particular transgenic mice line bearing the RET(Cys634Arg)
allele under the control of the calcitonin promoter develops both MTC and PTC
36
(Reynolds et al., 2001). Thus, under specific circumstances, point mutations in
RET can drive the generation of PTC. The low mitogenic activity of RET point
mutants compared to RET/PTC and the presence of the intracellular
juxtamembrane domain that exerts negative effects on mitogenic signalling of RET
oncoproteins provide a possible explanation for the rare association of MTC with
PTC (Melillo et al., 2004). The possibility that a small number of MTCs arise from
a common stem cell (possibly the ultimobranchial body) that may give rise to both
MTC and PTC has also been suggested (Kovacs et al., 1994).
1.3.5 RET in sporadic medullary thyroid carcinoma (sMTC)
Somatic RET mutations have been found in 40-50% of sporadic MTCs and, rarely,
in pheochromocytomas. The mutation at codon 918 is mostly predominant.
Somatic mutations at codons 630, 634, 639, 641, 768, 883, 922, and deletions
including codons 630 and 634 have also been described (Hofstra et al., 1994;
Zedenius et al., 1994; Eng et al., 1994,1995,1996b; Marsch et al., 1996; Romei et
al., 1996; Bugalho et al., 1997; Shirahama et al., 1998; Kalinin et al., 2001).
Tumors with a somatic codon 918 mutation appear to be more aggressive
(Schilling et al., 2001). However, the functional significance of sporadic RET
mutations in MTC pathogenesis is unclear. The distribution of the Met918Thr in
sMTC and related metastases is non-homogeneous, occurring only in
subpopulations and among subsets of multiple metastases, thus implying that the
codon 918 mutation can arise as an event in progression within a metastatic clone
or within a single tumor, or that MTC can be of polyclonal origin (Eng et al.,
1996b).
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Table 2. RET mutations in MEN 2 syndromes and sMTC
Exon Codon
Number
Amino acid
Change
Phenotype Reference
8 533 Gly to Cys FMTC Da Silva, 2004
10 603 Lys to Gln sMTC Rey, 2001
609 Cys to Arg
Cys to Tyr
Cys to Ser
MEN2A/FMTC
MEN2A
MEN2A
Mulligan, 1995; Eng, 1996a
Mulligan, 1994
Igaz, 2002
611 Cys to Tyr
Cys to Trp
Cys to Gly
Cys to Ser
MEN2A
MEN2A/FMTC
FMTC
MEN2A/FMTC
Mulligan, 1995; Eng, 1996a
Donis-Keller, 1993
Mulligan, 1995; Eng, 1996
Nishikawa, 2003
618 Cys to Phe
Cys to Ser
Cys to Gly
Cys to Arg
Cys to Tyr
Cys to Stop
MEN2A
MEN2A/FMTC
MEN2A
MEN2A/FMTC
MEN2A/FMTC
MEN2A
Mulligan, 1995; Eng, 1996
Donis-Keller,1993;Morita,1996
Mulligan, 1995; Eng, 1996
Donis-Keller,1993; Marsh, 1994¸
Donis-Keller, 1993
Mulligan, 1995; Eng,1996
620 Cys to Arg
Cys to Tyr
Cys to Phe
Cys to Ser
Cys to Gly
MEN2A/FMTC
MEN2A
MEN2A
MEN2A
MEN2A
Donis-Keller, 1993
Donis-Keller, 1993
Mulligan, 1995; Eng,1996
Oishi, 1995
Mulligan, 1993
11 630 Cys to Phe
Cys to Arg
FMTC
sMTC
Komminoth, 1995
Bugalho, 1997
634 Cys to Arg
Cys to Tyr
Cys to Phe
Cys to Gly
Cys to Trp
Cys to Ser
Cys to Arg
MEN2A
MEN2A/FMTC
MEN2A/FMTC
MEN2A
MEN2A
MEN2A/FMTC
sMTC
Donis-Keller,1993;Mulligan,1994
Mulligan, 1994
Mulligan, 1994
Mulligan, 1993
Mulligan, 1994
Mulligan, 1993; Eng, 1996
Zedenius, 1994; Romei, 1996;
Bugalho, 1997
634 and
640
Cys to Arg and
Ala to Gly
de novo MEN2A Tessitore, 1999
639 and
641
Ala to Gly and
Ala to Arg
sMTC Kalinin, 2001
13 768 Glu to Asp FMTC/sMTC Eng, 1995
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790 Leu to Phe MEN2A/FMTC Berndt, 1998
791 Tyr to Phe FMTC Berndt, 1998
14 804 Val to Leu
Val to Met
FMTC
FMTC
Bolino, 1995
Fattoruso, 1998
804 and
806
Val to Met and
Tyr to Cys
de novo MEN2B Miyauchi, 1999
778 and
804
Val to Ile and
Val to Met
FMTC Kasprzak, 2001
15 883 Ala to Phe de novo MEN2B
sMTC
Smith, 1997
Marsh, 1996
891 Ser to Ala FMTC
FMTC and Pheo
Hofstra, 1997
Jimenez, 2004
16 918 Met to Thr MEN2B
sMTC
Carlson, 1994a
Eng, 1994; Hofstra, 1994
922 Ser to Phe sMTC Kalinin, 2001
Exon Base pairs
duplication
Codon
Number
Amino
acids
inserted
Phenotype Reference
8 9 bp 532-534 EEC FMTC Pigny, 1999
11 12 bp 631-634 HELC MEN2A Hoppner, 1997
9 bp 634-636 CRT MEN2A Hoppner,1998
1.3.6 Diagnosis and management of MEN 2
The prognosis for MEN 2 patients is very good with early diagnosis and
intervention. Thus, adequate testing is required to screen subjects at risk for MTC.
Consensus was reached at the Sixth International Workshop on Multiple Endocrine
Neoplasia that the decision to perform thyroidectomy in MEN 2 should be based
predominantly on the result of RET mutation testing, rather than on calcitonin (CT)
testing (Lips, 1998). Currently, early genetic screening for RET mutations is
considered the standard care for MEN 2 as patients having a MEN 2-specific
germline mutation have a high risk of developing MTC (Gimm et al., 2001).
Because of the critical implications of finding a RET mutation, all cases of sporadic
MTC or apparently isolated and non-familial pheochromocytoma should be also
tested for germline RET mutation (Brandi et al., 2001).
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The specifically mutated codon of RET correlates with the MEN 2 variant,
the average age of onset of MTC, and the aggressiveness of MTC. Thus, the
mutated RET codon and the features within the family should receive careful
attention in planning thyroid management. The RET codon mutations can be
divided into three levels of risk from MTC (Brandi et al., 2001). Children with
MEN 2B-associated MTC are classified as level 3 or as having the highest risk
from aggressive MTC and should have thyroidectomy within the first 6 months and
preferably within the first month of life. Thyroid surgery for MEN 2B should
include a central node dissection. Children with any RET codon 611, 618, 620, or
634 mutation are classified as having a high risk for MTC (level 2) and should
undergo thyroidectomy performed before the age of 5 years. Children with RET
codon 609, 768, 790, 791, 804, and 891 mutations are classified as having the least
risk among the three RET codon mutation stratification categories (level 1). They
should have a total thyroidectomy as well. The biological behavior of MTC in
patients with these mutations is variable, but, in general, MTC grows more slowly
and develops at a later age than with the high risk mutations.
In order to simplify the detection of RET missense mutations, a method for
the rapid mutation analysis of gene sequences has been proposed using an
oligonucleotide microarray instead of the commonly used analysis of RET
mutations by single-strand conformational polymorphism or by direct sequencing
(Kim et al., 2002). This might represent an effective diagnostic genetic tool to
detect MEN 2 mutations at early stages.
The prognosis for unresectable or metastatic MTC is poor because radiation
and chemotherapy regimens have only a limited palliative role (Cohen and Moley,
2003; Wells and Franz, 2000). Targeting the enzymatic activity of tyrosine kinases
by small molecule inhibitors could help in developing new therapeutic strategies
for RET-associated diseases (Shawver et al., 2002). The tyrosine kinase inhibitors
STI571 (Gleevec, Imatinib), genistein, allyl-geldanamycin, and arylidene 2-
indolinone (RPI-1) selectively inhibit cell growth and RET tyrosine kinase activity
in vitro (Cohen et al., 2002; Lanzi et al., 2000; Lanzi et al., 2003). In mice, oral
daily RPI-1 treatment inhibits the growth of human medullary thyroid carcinoma
xenografts by 81% (Cuccuru et al., 2004). Two indolocarbazole derivatives, CEP-
701 and CEP-751, inhibit RET-MEN 2A and tumor growth in MTC cell xenografts
(Strock et al., 2003). The pyrazolo-pyrimidine PP1 blocks tumorigenesis induced
by RET/PTC oncogenes and induces degradation of activated membrane-bound
RET receptors through proteosomal targeting (Carlomagno et al., 2002a; Carniti et
al., 2003). Another pyrazolo-pyrimidine, PP2, and the 4-anilinoquinazoline
ZD6474 also display a strong inhibitory activity towards constitutively active
oncogenic RET kinases (Carlomagno et al., 2003; Carlomagno et al., 2002b).
However, two naturally occurring mutations of valine 804 of RET cause resistance
to pyrazolo-pyrimidines and 4-anilinoquinazolines (Carlomagno et al., 2004).
These compounds show promise for the treatment of human cancers sustaining
oncogenic activation of RET. Furthermore, understanding the mechanism(s) of
resistance can be of aid for improving the design of small molecule inhibitors and
the selection of patients to be treated. Furthermore, molecular mimics directed
toward specific mutations of RET (Cerchia et al., 2003) and transductional
targeting of dominant-negative RET mutants to tumor cells (Drosten et al., 2002;
2003; 2004) might provide promising new alternatives to target the RET oncogene
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in terms of selectivity, safety and efficacy. Taken together, multiple possibilities
have been and continue to be employed for improving therapy by inhibition of
oncogenic RET signalling and, in general, of MTC.
1.4 RET GERMLINE INACTIVATING MUTATIONS IN
HIRSCHSPRUNG’S DISEASE
Hirschsprung’s disease (HSCR, Online Mendelian Inheritance in Men OMIM 
142623), or congenital intestinal aganglionosis, is a relatively common disorder of
neural crest migration (one in 5000 live births) leading to defects in enteric
innervation, intestinal obstruction or chronic constipation (reviewed by Parisi and
Kapur, 2000). The disease is characterised by the absence of intramural nervous
plexuses, namely the myenteric plexus (or Auerbach plexus) and the submucous
plexus (or Meissner plexus), along variable lengths of the hindgut. The neural crest
(NC) cells that contribute to the formation of the enteric nervous system (ENS)
originate from the vagal, truncal and sacral regions of the neural tube (Fig. 9)
(Goyal and Hirano, 1996; Gershon, 1997; Taraviras and Pachnis, 1999). Most
HSCR cases are sporadic. However, 15-20% are familial with a strong genetic
basis, although simple Mendelian inheritance is rarely observed, as the disease is
multifactorial, with contributions from several genes, low penetrance, variable
expression of aganglionosis, and sex bias (Amiel and Lyonnet, 2001). Different
forms of inheritance can be distinguished. Families mostly follow an autosomal
dominant form of inheritance with incomplete penetrance (Edery et al., 1994).
Sporadic HSCR variants are thought to arise as a result of multifactorial
inheritance, whereas some HSCR variants being associated with distinct
malformations, such as Waardenburg syndrome, are mostly autosomal recessive or
due to chromosomal abnormalities, as in the case in the association with Down’s 
syndrome (Amiel and Lyonnet, 2001).
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Figure 9. The different subpopulations of neural crest cells contributing to the
formation of the enteric nervous system (ENS). The ENS is derived from the
neural crest (NC) cells. NC cells that contribute to the formation of the ENS
originate from the vagal, truncal and sacral regions of the neural tube. The vagal-
crest-derived cells colonize the entire intestine and give rise to the superior cervical
ganglion (SCG) and to the thyroid C cells. These NC cells, which constitute the
sympatho-enteric lineage, co-express RET and GFR1 and are dependent on their
interaction with GDNF during their migration or at the site of gangliogenesis.
GDNF is expressed in the mesenchyme of the gut wall. The trunk NC cells, named
sympatho-adrenal lineage, populate the foregut and the sympathetic chain posterior
to the SCG and are RET/GDNF-independent. Finally, the sacral NC cells colonize
the post-umbilical bowel. The arrows indicate the directions of migration. (From
Manié et al., 2001).
Mutations in the RET gene are associated with approximately half of
familial cases and a small fraction of sporadic cases (Angrist et al., 1995; Attié et
al., 1995; Eng, 1996). Mutations in genes that encode GFLs (GDNF and NRTN);
components of the endothelin (EDN) type B receptor pathway (EDNRB, EDN3,
ECE-1); the transcription factors, SOX10 and SMAD-interacting protein-1 (SIP1),
have been identified in HSCR patients (Parisi and Kapur, 2000; Cacheux et al.,
2001; Wakamatsu et al., 2001). A subset of these mutations is associated with
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anomalies of pigmentation and/or hearing loss. Mutations at individual loci are
neither necessary nor sufficient to cause clinical disease. For almost every HSCR
gene, incomplete penetrance of the HSCR phenotype has been observed, probably
due to genetic modifier loci. Associations of several polymorphisms of RET with
HSCR have been reported (Borrego et al., 1999, 2000, 2003; Gath et al., 2001;
Fitze et al., 1999, 2002, 2003).
Molecular genetic analyses have revealed that, in particular, the interaction
between mutations in the genes encoding RET and EDNRB are central in the
pathogenesis of HSCR (Carrasquillo et al., 2002). In accordance, Ret+/-
heterozygous mice show no intestinal aganglionosis and EdnrB-null homozygotes
show aganglionosis only in the very distal colon. When the Ret+/- mice are crossed
with mice carrying different combinations of EdnrB-null allele, the decreasing
dosage of EDNRB dramatically increases the length of aganglionosis (McCallion
et al., 2003). Thus, cross-talk between EDNRB and RET is essential for both
normal development of the enteric nervous system and the pathogenesis of
Hirschsprung’s disease. 
RET mutations are spread throughout the coding sequence and include
deletion, insertion, frameshift, nonsense, and missense mutations (Eng and
Mulligan, 1997; Parisi and Kapur, 2000). The majority of these mutations causes
either a reduction of dosage of the RET protein or the loss of RET function (Parisi
and Kapur, 2000; Iwashita et al., 2001), suggesting that HSCR results from RET
haploinsufficiency. Functional consequences of HSCR mutations correlate with
their position in the coding sequence and they have been classified tentatively into
four groups (Fig. 10) (Pelet et al., 1998; Iwashita et al., 2001; Manié et al., 2001).
Class I mutations, located within the extracytoplasmic domain, disrupt RET
maturation and inhibit its translocation at the plasma membrane (Carlomagno et al.,
1996; Iwashita et al., 1996). Class II mutations cause the replacement of one of
four extracytoplasmic cysteine residues (Cys609, 611, 618, and 620) by a different
amino acid. Germline mutations of the very same cysteine residues are responsible
also for MEN 2A and FMTC and in some individuals MEN 2A/FMTC co-
segregates with HSCR (Mulligan et al., 1994). Class III mutations affect the
tyrosine kinase domain and perturb the catalytic activity (Iwashita et al., 2001;
Takahashi et al., 1999). Class IV mutations do not decrease tyrosine kinase activity
but specifically interfere with the binding of RET signalling components such as
Shc, PLC-, FRS2, and IRS-1 (Lorenzo et al., 1997; Geneste et al., 1999; Iwashita
et al., 2001; Melillo et al., 2001a,b). Additional mechanisms than RET loss-of-
function might be implicated in the etiology of HSCR. Accordingly, it has been
proposed that certain missense mutations in RET involved in HSCR could have a
dominant-negative effect (Pasini et al., 1995; Cosma et al., 1998) or convert RET
into a constitutive inducer of apoptosis (Bordeaux et al., 2000).
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Figure 10. Functional consequences of RET mutations found in
Hirschsprung’s disease (HSCR).Classification of missense mutations involved in
HSCR, according to their molecular consequences on RET function. CAD,
cadherin domain; CYS, cysteine-rich domain; TM, transmembrane domain; TK,
tyrosine kinase domain; boxed, mutations leading to a partial loss of RET kinase
activity. Mutations of Class II are associated with both HSCR and MEN
2A/FMTC. (Modified from Manié et al., 2001).
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2. AIMS OF THE PRESENT STUDY
When this study was initiated, RET receptor tyrosine kinase was still an orphan
receptor. Studies on RET signalling were carried out using the oncogenic forms of
RET. The aims of the current study were to understand the role of transforming
pathways triggered by RET activated by point mutations or chromosomal
rearrangements. As Shc proteins are constitutively phosphorylated in tumor cells
with activated tyrosine kinases, the first aim was to investigate the interaction of
the different oncogenic forms of RET with Shc. We identified the Shc docking site
in RET tyrosine kinase and the Shc domains involved in the interaction. We also
characterised the role of Shc signalling in the transforming pathway triggered by
RET/PTC2 oncoprotein. During the course of these studies, it became clear that the
Tyr1062 of RET plays a crucial role in most of the signalling pathways activated
by RET as a docking site for multiple adaptor proteins. Also the ligand of RET
became known. We analysed the role of the Tyr1062 in the transforming and
differentiating cellular activities promoted by ligand-stimulated RET isoforms. The
characterisation of RET-mediated signalling pathways led us to further investigate
the biology of gain-of-function and loss-of-function mutations of RET associated
with cancer syndromes and developmental processes. Finally, we addressed RET-
independent GDNF signalling and investigated the mechanism of RET-
independent responses to GDNF in cell and organ cultures.
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3. MATERIALS AND METHODS
The methods used are described in detail in the “Materials and Methods” section of 
the respective publications. Experimental procedures using laboratory animals were
performed according to ethical guidelines approved by local authorities.
3.1 Cell lines
Mammalian cell culturing was carried out in the medium mentioned in Table 3,
supplemented with 100U/ml penicillin and 50g/ml streptomycin.
Name Description Used in Culture
medium
COS7 African green monkey kidney fibroblasts,
SV40 transformed, ATCC CRL-1651
I, II, IV, V DMEM + 10%FCS
NIH 3T3 Mouse embryo fibroblasts, ATCC CRL-1658 I, II, III, IV, V DMEM + 10%FCS
293T Human fetus kidney epithelial cells, expressing
the transforming gene of adenovirus 5, ATCC
CRL-1573
II, III, IV DMEM + 10/FCS
SK-N-MC Human brain epithelial cells, from metastatic
site: supra-orbital area neuroepithelioma,
ATCC HTB-10
III RPMI 1640 +
15%FCS
MDCK Dog adult kidney epithelial cells, ATCC CCL-
34
III, IV, V MEM + 10%FCS
SHEP Human neuroblastoma cells V RPMI 1640 +
10%FCS
Neuro-2A Mouse neuroblastoma cells, ATCC CCL-131 V RPMI 1640 +
10%FCS
Table 3. The cell lines used with their ATCC (American Type Culture Collection)
identification number.
3.2 Antibodies, growth factors, recombinant proteins, chemical inhibitors
Name Description Reference or source Used in
Anti-Ret common I polyclonal (against 1011-1027
amino acids of RET)
Borrello et al., 1996 I, II, III
Anti-Ret common II polyclonal (against 1000-1014
amino acids of RET)
Borrello et al., 1996 III
Anti-Ret C-19 polyclonal, RET9 specific Santa Cruz Biotechnology,Inc. IV, V
Anti-Ptyr monoclonal, 4G10 Upstate–Cell Signaling
Solutions
I, II, III,
IV, V
Anti-Shc monoclonal Borrello et al., 1996 I, II
Anti-Shc polyclonal Upstate–Cell Signaling
Solutions
I, II, III
Anti-Sos1 polyclonal Upstate–Cell Signaling
Solutions
II
Anti-HA monoclonal, 12CA5/16B12 Berkeley Antibody
Company/Covance
II
Anti-Erk1/2 monoclonal New England Biolabs/Cell
Signaling
II, III
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Anti-phosphoErk1/2 monoclonal New England Biolabs/Cell
Signaling
II, III
Anti-Akt monoclonal Cell Signaling III
Anti-phospho-Akt monoclonal Cell Signaling III
Anti-p38 polyclonal Cell Signaling III
Anti-PLC1 polyclonal Upstate–Cell Signaling
Solutions
IV
Anti-pY418 polyclonal BioSource International V
Anti-Src polyclonal BioSource International V
Anti-Met polyclonal Santa Cruz Biotechnology, Inc. V
Anti-pan-
cytokeratin
monoclonal Sigma-Aldrich V
GDNF human recombinant GDNF Alomone labs or Cephalon Inc. or
R&D Systems
III, IV, V
NRTN human recombinant NRTN Alomone labs III
HGF human recombinant HGF Sigma-Aldrich V
SGFR1 recombinant Rat GFR1/Fc
chimera
R&D Systems III
ATF2 (1-96) recombinant substrate for p38
MAPK
Santa Cruz Biotechnology, Inc. III
PD98059 inhibitor of MEK1 Calbiochem III
Wortmannin inhibitor of PI3K Calbiochem III
SB203580 inhibitor of p38 MAPK Calbiochem III
SB202190 inhibitor of p38 MAPK Calbiochem III
SB202474 negative control for MAPK
inhibition
Calbiochem III
RPI1(Cpd1) inhibitor of RET kinase Lanzi et al., 2000 III
PP2 inhibitor of Src family kinases Calbiochem V
Table 4. Antibodies, growth factors, recombinant proteins and chemical inhibitors
used.
3.3 DNA constructs
Expression plasmid Source/Reference Used in
RET9 (short isoform) Prof. Bruce Ponder, Borrello et al., 1995
Dr. Marc Billaud, Rossel et al., 1997
I , III, IV
V
RET51 (long isoform) Prof. Bruce Ponder, Lorenzo et al., 1997 III
RET9-C620R IV IV
RET9-C634R Prof. Bruce Ponder, Borrello et al., 1995 I, III, IV
RET51-C634R Prof. Bruce Ponder, Lorenzo et al., 1997 III
RET9-K758R IV III, IV
RET9-S765P IV IV
RET9-S767R IV IV
RET-E768D IV IV
RET9-M918T Prof. Bruce Ponder, Borrello et al., 1995 I
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RET9-Y1062F III III
RET51-Y1062F III III
RET51-Y1096F III III
RET9-C634R/Y1062F Dr. Darrin Smith, Lorenzo et al., 1997 III
RET51-C634R/Y1062F Dr. Darrin Smith, Lorenzo et al., 1997 III
RET51-Y1062F/Y1096F III III
RET/PTC2-iso9 (short isoform) Bongarzone et al., 1993 I, II
RET/PTC2-iso51 (long isoform) Bongarzone et al., 1993 I, II
RET/PTC2-Y539F iso9 Borrello et al., 1996 I
RET/PTC2-N583A iso9 II II
RET/PTC2-N583A iso51 II II
RET/PTC2-Y586F iso9 I I, II
RET/PTC2-Y586F iso51 II II
RET/PTC2-K282R iso9 I I, II
SHC-HA Dr. Mikhail Gishizky, Hill et al., 1996 II
SHC-Y317F-HA Dr. Mikhail Gishizky, Hill et al., 1996 II
SHC-R401K-HA Dr. Mikhail Gishizky, Hill et al., 1996 II
SHC-PI-HA Dr. Mikhail Gishizky, Hill et al., 1996 II
pEGFP-N1 vector Clontech Laboratories, Inc. III
GRB2 Dr. Bruce Mayer, Tanaka et al., 1995 III
DN GRB2-W36,193K Dr. Bruce Mayer, Tanaka et al., 1995 III
GFP-GFR1 V V
c-Src Dr. Joan Brugge, Lee et al., 1999 V
DN c-Src Dr. Joan Brugge, Rusanescu et al., 1995 V
Activated c-Src V V
Table 5. Expression plasmids used.
3.4 Transfection of cell lines
COS7 cells were transiently transfected by the DEAE-dextran method (I, II,
IV) or using the FuGene 6 reagent (Roche Diagnostic) according to
manufacturer’s instruction (V). For transfections by the DEAE-dextran method, the
cells were seeded at the density of 1x106 cells/10cm plate in complete medium and
grown for 24h prior to incubation in serum free medium with 500 g/ml DEAE-
dextran, 1g/plate of plasmid DNA, and 20g/plate of carrier DNA. After 30 min,
the medium was removed and cells incubated 3h in complete medium plus 100M
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chloroquine. The cells were harvested 72h after transfection for
immunoprecipitation.
NIH 3T3 cells (2x105 cells/10cm plate) were stably transfected by the
calcium phosphate precipitation method (Bongarzone et al., 1993) using 0.2-0.5g
of plasmid DNA and 40 g of carrier DNA. G418-resistant colonies and foci of
transformed cells were selected in complete medium + G418 and DMEM +
5%FCS, respectively. G418-resistant colonies and transformation foci were either
fixed and counted or isolated for further studies 14-21 days after transfection,
respectively (I, II, III, IV). Transient transfections of NIH 3T3 cells were
performed with the FuGene 6 reagent (Roche Diagnostic) according to
manufacturer’s instruction (V).
293T cells (1x106 cells/10cm plate) were transiently transfected by
calcium phosphate precipitation method with 1-5 g of plasmid DNA. Cells were
starved in serum-free medium for 12h before protein extraction (II, III, IV).
SK-N-MC cells were stably transfected using the ExGen500 reagent (MBI
Fermentas) according to manufacturer’s instruction (II).
MDCK cells were stably transfected prior to confluence using the FuGene
6 reagent (Roche Diagnostic) according to manufacturer’s instruction (II, IV, V). 
Transient transfections of MDCK cells were performed with the Lipofectamine
2000 reagent (Invitrogen Corp.) following the supplier’s protocol (II). For the 
infection of MDCK cells, 5 pfu/cell of adenovirus diluted in serum-free medium
with 15 mM Hepes, pH 7.4 were used (V).
3.5 Adenovirus construction
The adenoviruses were generated using the pAdEasy recombinant system as
described in He et al. (1998). Briefly, the Src mutants were cloned in the shuttle
vector pAdTrack, recombined in bacteria with the adenoviral vector pAdEasy,
linearized, transfected and amplified in 293A cells. The virus particles were
purified on CsCl gradients, dialysed, and titered in 293A cells.
3.6 Immunoprecipitations
The buffers used for cell lysis and following immunoprecipitation are: Triton lysis
buffer (10 mM sodium phosphate, pH 7, 100 mM NaCl, 1% Triton X-100, 5 mM
EDTA, supplemented with a protease inhibitor cocktail (Roche Diagnostic) and
phosphatase inhibitor 1 mM Na3VO4); PLC lysis buffer (50 mM Hepes, pH 7.4,
150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 10
mM Na4P2O7, 10 mM NaF, 1 mM Na3VO4, supplemented with protease inhibitors
PMSF, aprotinin, leupeptin, and pepstatin or a protease inhibitors cocktail); RIPA
lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Nonidet
P-40); p38 lysis buffer (25 mM HEPES, 20 mM -glycerol-phosphate, 0.1 mM
Na3VO4, 0.1% Triton X-100, 0.3 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5
mM DTT, supplemented with a protease inhibitor cocktail).
Immunoprecipitations were carried out by incubating the lysates at 4C
with protein A- or protein G-Sepharose (Amersham Biosciences) precoated with
specific antibodies.
For total cell lysates, boiling SDS lysis buffer (62.5 mM Tris-HCl, pH 6.8,
2% SDS) was used.
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3.7 GST proteins
The PTB domain of Shc and SH2 domains of Shc and Grb2 were cloned into
pGEX-3X vector (Amersham Biosciences) and expressed in DH5or BL21
Escherichia coli cell line as glutathione-S-transferase (GST) fusion proteins.
Bacterial cultures were grown in Luria medium and incubated for 3-6 hours
following induction with 1 mM IPTG. Proteins were purified on glutathione-
Sepharose beads.
3.8 Western blotting
Immunoprecipitates and total cell lysates were separated by SDS-PAGE and
transferred to nitrocellulose membrane. Immunodetection was performed using
specific primary antibodies, biotinylated anti-mouse or anti-rabbit secondary
antibodies (DAKO) and streptavidin-biotin HRP-conjugate (Amersham
Biosciences) followed by ECL detection (Amersham Biosciences). When 125I-
protein A was used, the membranes were exposed to storage phosphor screen films
and analysed with PhosphorImager apparatus (Molecular Dynamics).
3.9 In vitro kinase assays
For the RET kinase assay, the anti-RET immunoprecipitates were washed
twice with PLC lysis buffer, once with kinase buffer (50 mM Hepes, pH 7.2, 20
mM MnCl2, 5 mM PMSF), and incubated for 15 min at 4C in 20 l of kinase
buffer containing 0.5 mM DTT, 4 Ci 32PATP (Amersham) diluted with
unlabeled ATP to the final concentration of 26 pmol ATP per sample, and 50 M
MBP. The reactions were terminated by boiling in reducing Laemmli buffer and
separated by SDS-PAGE followed by autoradiography and quantification of
radioactivity using PhosphorImager (Molecular Dynamics).
For the phosphorylation of synthetic peptides by RET, the kinase reaction
was carried out at 37C for 1h in the presence of 250 mM of peptide and
terminated by adding 30% acetic acid. The peptides contained in the mixture were
dried, resuspended in water and separated by reverse phase HPLC followed by
TLC and autoradiography.
For p38 kinase assay, the GST-ATF2 immunocomplexes were washed three
times with washing buffer (20 mM HEPES, 50 mM NaCl, 2.5 mM MgCl2, 0.1 mM
EDTA, 0.05% Triton X-100) and incubated at 30C for 30 min in the incubation
buffer (50 mM -glycerol-phosphate, 0.1 mM Na3VO4, 10 mM MgCl2,10 Ci
32PATP). The reactions were terminated by adding washing buffer and separated
by SDS-PAGE followed by autoradiography.
3.10 Biotinylation of cell surface proteins
Biotinylation of MDCK(RET) cells was performed with ECL Protein Biotinylation
Module (Amersham Biosciences) according to the manufacturer’s instructions. 
3.11 125I-labeled GDNF and HGF binding, chemical cross-linking
GDNF and HGF were enzymatically iodinated with 125INaI (Amersham
Biosciences) with lactoperoxidase as described (Lindahl et al., 2001). 125I-GDNF
or 125I-HGF were allowed to bind to cell monolayers for 1-2 h on ice in binding
buffer (DME/15 mM Hepes, pH 7.5, 0.2% BSA), washed, and chemically cross-
linked for 30 min at RT using BS3, DSS, DSP, or EDC with sulfo-NHS (Pierce
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Chemical Co.). Cells were washed, lysed, and immunoprecipitated. Gels were dried
and analysed by phosphorimaging in a BAS Reader 1800 (Fuji).
3.12 Cell migration and chemotaxis assays
MDCK cells were suspended in medium containing 10% fetal calf serum, and
seeded into 24-well cell culture inserts with filters (Boyden chambers) (pore size, 8
m; Falcon). The assay was carried out as described (Tang et al., 1998). In another
chemotaxis assay, 3.5-cm dishes were coated with collagen I solution, and MDCK
cells were seeded on top of it. GDNF-soaked agarose beads, prepared as described
(Sainio et al., 1997), were put on the gel before it solidified.
3.13 Branching tubule formation assay in collagen gel
Trypsinised MDCK cells were mixed 1:3 with collagen type I solution and plated.
Medium containing 10% fetal calf serum was overlaid on the gels with or without
growth factor. Cells in collagen were cultured for 3 days, fixed by 3%
glutaraldehyde in PBS, and counted.
3.14 Cell apoptosis assays
Apoptotic cells were detected by TUNEL histochemistry using the ApopTag
Fluorescein in situ Apoptosis Detection Kit (Intergen Co.) or in situ Cell Death
Detection Kit (Boehringer), according to the manufacturer’s instructions. The 
terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)
process was used to incorporate fluorescein at free 3OH DNA ends of apoptotic
cells. TUNEL reactivity was examined with a fluorescence microscopy.
3.15 Cell proliferation assays
For BrdU assay, cells were seeded on coverslips in full-serum medium.
Cells were starved for 24 h and the next day GDNF was added. Plates were
cultured for 24 h or 48 h. One hour before the fixation BrdU (1:1000, Amersham
Biosciences) was added. Cells were fixed with 70% ethanol and washed with PBS.
Immunocytochemistry was carried out using the Anti-Bromodeoxyuridine +
Nuclease Kit (Amersham Biosciences).
For MTT assay, cell proliferation was evaluated using the Cell Proliferation
Kit I (MTT, Roche Diagnostic), according to the manufacturer’s instructions.
3.16 Anchorage-independent growth assay
6.0-cm dishes were coated with a bottom layer of 0.5% Noble agar (Agarose type
VII, Sigma) in full-serum medium, and NIH 3T3 or MDCK cells in 0.33% Noble
agar were seeded on top of it. The colonies were dyed 2 and 3 wk later with p-
iodonitrotetrazolium violet (Sigma).
3.17 Kidney cultures
Kidney rudiments were isolated from NMRI mouse embryos at E11 and cultured
on Nuclepore filters (pore size, 1m) on top of metal grid. The full-serum medium
was supplemented in some dishes with GDNF. After 4 days of culture, the kidney
rudiments were fixed in ice-cold methanol and immunohistochemically stained as
whole-mounts as described (Sainio et al., 1997).
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4. RESULTS AND DISCUSSION
4.1 SHC PROTEINS ARE CONSTITUTIVELY PHOSPHORYLATED ON
TYROSINE IN TUMOR CELLS WITH TK GENE ALTERATIONS (I, II)
Shc proteins are constitutively phosphorylated in tumor cells with activated
tyrosine kinases (TKs), namely EGFR, Met, RET, ErbB-2, Bcr-Abl, and form
stable complexes with the activated TKs (Pelicci et al., 1995). Shc is not
phosphorylated in non-transformed cell lines and normal tissues, unless they are
stimulated with the appropriate growth factors. The constitutive tyrosine
phosphorylation of the transforming RET proteins derived from oncogenic
rearrangements in papillary thyroid carcinomas (Grieco et al., 1990; Lanzi et al.,
1992; Bongarzone et al., 1993) or from gain-of-function mutations causing MEN 2,
prompted us to investigate the interaction of the different oncogenic forms of RET
with Shc and the molecular mechanisms responsible for the formation of the RET-
Shc complexes associated with human cancer.
4.1.1 Shc associates with RET oncoproteins
NIH 3T3 cell lines expressing oncogenic forms of RET acquire a transformed
phenotype (Borrello et al., 1995). In order to analyse the levels of Shc
phosphorylation in NIH 3T3 cells transformed by RET oncoproteins, serum-
starved cells were lysed and Shc proteins were immunoprecipitated and analysed
by immunoblotting. Shc proteins were phosphorylated in cells expressing either
isoforms of RET/PTC2, RET-MEN 2A, or RET-MEN 2B, whereas barely
phosphorylated Shc proteins were present in unstimulated wild-type RET-
expressing cells (I, Fig. 1). It thus appears that all RET oncoproteins are able to
recruit and activate Shc. The oncogenic RET proteins, but not wild-type RET, are
also constitutively phosphorylated on tyrosine and co-immunoprecipitate with Shc,
indicating the formation of stable complexes. In addition, as the methionine to
threonine mutation associated with MEN 2B changes the substrate specificity of
the RET receptor (Songyang et al., 1995; Pandit et al., 1996), our results indicate
that Shc is a common substrate for wild-type and MEN 2B RET kinase.
To understand the molecular mechanisms responsible for the formation of
the RET-Shc complexes, we took advantage of GST fusion proteins containing
either the SH2 or the PTB domain of Shc. Glutathione agarose-immobilised GST-
SH2(Shc) or GST-PTB(Shc) proteins were incubated with cell lysates and the
recovered proteins immunoblotted with the specific antibodies (I, Fig. 2). Both the
SH2 and the PTB domains of Shc were able to bind RET/PTC2. The pretreatment
of cell lysates with SDS and boiling that dissociates protein-protein interactions did
not afect the “pul-down” of RET proteins, supporting the possibility of direct 
binding not mediated by adaptor proteins. By decreasing the amount of cell lysates,
we estimated that the PTB domain of Shc has a higher affinity for RET/PTC2 than
the SH2 domain, indicating that it might serve as the major or the unique binding
site for RET. However, one might envisage that Shc interacts with two RET
molecules by using both domains. This may play a role in the stabilisation of
receptor dimers, as hypothesized for EGFR and ErbB-3 (Prigent et al., 1995). No
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differences between RET9 and RET51 were observed in the binding of Shc,
suggesting that the main docking site for Shc resides in the amino acid sequence
common to both isoforms.
4.1.2 Identification of putative Shc docking sites on RET
SH2 and PTB domains recruit specifically tyrosine-phosphorylated proteins into
signalling complexes (Kavanaugh and Williams, 1994). SH2 domain binding
specificity derives from peptide sequences carboxyl-terminal to phosphotyrosine
(pTyr), whereas the PTB domain interacts specifically with sequences amino-
terminal to pTyr (Trub et al., 1995). Five residues amino-terminal to pTyr are
required for PTB domain high affinity binding, whereas all residues carboxyl-
terminal to tyrosine are unimportant for this interaction. We used a series of
synthetic tyrosine phosphorylated peptides corresponding to the sequence
surrounding the tyrosine residues of the cytoplasmic region of RET, to compete
with the binding between RET and SH2 and PTB domains of Shc. Peptides
comprised residues from position -4 to +5 or -6 to +1 relative to pTyr (I, Table 1).
We found that only the two peptides spanning Tyr586 of RET/PTC2 and specific
for either RET9 or RET51 were able to compete with and reduce the association
between RET/PTC2 and the PTB domain expressed as a GST fusion protein (I, Fig.
3A). The binding between RET/PTC2 and the SH2 domain was inhibited by two
phosphorylated peptides spanning Tyr539 and RET9-specific Tyr586 (I, Fig. 3B).
Tyr586 of RET/PTC2, corresponding to Tyr1062 of RET, is the last amino acid but
one before the divergence of the two RET isoforms (I, Fig. 5A). The residues
amino-terminal to Tyr586, which are required for PTB domain binding, are
common to both isoforms. Indeed, both peptides spanning the Tyr586 inhibited the
binding with the PTB domain. The sequence NXXpY and a non-polar residue in -5
position are strictly required for PTB(Shc) domain binding to activated growth
factor receptors (Dikic et al., 1995; Van der Geer et al., 1996b; Laminet et al.,
1996). Indeed, the Tyr586 is the only cytoplasmic tyrosine of RET with asparagine
in -3 position and isoleucine in -5 position. The amino acids carboxy-terminal to
Tyr586, which are crucial for the affinity towards the SH2 domain, differ between
the two RET isoforms. Interestingly, only the peptide comprising residues
surrounding Tyr586 specific of RET9 competed for binding with the SH2 domain,
suggesting that RET9 but not RET51 binds the SH2 domain of Shc. Differences
between the two isoforms of RET in binding the SH2 domain of Shc might reflect
differences in the specific downstream interactions and/or the magnitude of the
transduced signals.
By using synthetic peptides encompassing Tyr539 or Tyr586 and
employing them as substrates in in vitro kinase reactions, we showed that both
these tyrosine residues are auto- or trans-phosphorylation sites of RET (I, Fig. 4;
Borrello et al., 1996).
4.1.3 Tyr586 of RET/PTC2 is the docking site for Shc
In order to determine whether Tyr539 and Tyr586 of RET/PTC2 are docking sites
for Shc, we introduced the tyrosine to phenylalanine substitution at codons 539 or
586 of both RET isoforms by site-directed mutagenesis and analysed the ability of
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the RET/PTC2-Y539F and RET/PTC2-Y586F mutant proteins to form complexes
with Shc (I, Fig. 6). RET/PTC2 lacking Tyr539, which is a docking site for
PLCBorrello et al., 1996), was able to bind Shc as efficiently as wild-type
RET/PTC2. In contrast, both RET isoforms devoid of Tyr586 were incapable of
binding Shc (I, Fig. 6; II, Fig. 2B). The Y586F mutation also abolished the ability
of RET/PTC2 to bind either the SH2(Shc) or the PTB(Shc) domain expressed as a
GST fusion protein, indicating that the presence of phosphorylated Tyr586 is
required for the interaction between RET and Shc.
4.1.4 Asn583 of RET/PTC2 is required for high affinity binding of Shc
In order to further characterise the role of the PTB domain of Shc in the interaction
with RET, we introduced an asparagine to alanine substitution at codon 583 of
RET/PTC2 by site-directed mutagenesis. As mentioned above (see section 4.1.2),
asparagine in the -3 position relative to pTyr is strictly required for PTB domain
binding to growth factor receptors. Cell lysates from COS7 cells expressing
RET/PTC2-N583A were used for “pul-down” assays with PTB(Shc) or SH2(Shc) 
domains expressed as GST fused proteins. The mutation of the asparagine
completely abrogated the ability of both RET/PTC2 short and long isoforms to
bind the PTB(Shc) domain (II, Fig. 2A). Co-immunoprecipitation assays confirmed
that not only the docking site Tyr586 but also the Asn583 is required for high
affinity binding of Shc to RET (II, Fig. 2B). These results also confirm the major
role of the PTB domain in Shc-RET interactions.
4.1.5 Asn583 and Tyr586 are both required for transforming activity of RET/PTC2
oncogene
Tyrosine phosphorylation of RET/PTC2 oncoproteins is associated with their
transforming activity, evaluated as the ability to induce foci of transformed cells in
NIH 3T3 cells, anchorage-independent growth in soft agar, and in vivo tumor
formation (Borrello et al., 1996). To examine the functional consequences of the
inability of RET/PTC2-N583A and RET/PTC2-Y586F to interact with and
phosphorylate Shc, we analysed their oncogenic activity by an NIH 3T3 focus
formation assay. The transforming ability of both RET isoforms lacking of the Shc
docking site was almost abolished, less than 1/100 of that displayed by RET/PTC2
(II, Fig. 3 and Table 1). Unexpectedly, also the mutation of the asparagine at codon
583 required for PTB domain binding completely abrogated the transforming
activity of RET/PTC2. The correlation between the defect of Shc activation and the
lack of transforming activity of RET/PTC2 mutant proteins impaired in Shc
binding strongly supports a key role for Shc in the transforming activity of RET.
However, our results do not exclude the role of other possible Tyr586-binding
signal transducers having the same asparagine requirement in position -3 relative to
pTyr.
4.1.6 Transforming activity of RET/PTC2 depends on activation of Shc
In order to discriminate between the contribution of Shc from other possible signal
transducers in the transforming activity of RET/PTC2 in our cell model system, we
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used Shc mutant proteins with a dominant interfering effect on the activation of
endogenous Shc (Hill et al., 1996), namely Shc-Y317F (deficient in Grb2
interaction), Shc-R401K (with inactivated SH2 domain), and Shc-PI (lacking the
PTB domain) (II, Fig. 4A). The Shc mutant proteins were transiently expressed in
293T cells, and their ability to co-immunoprecipitate with RET/PTC2 was verified.
Shc-Y317F was able to bind RET/PTC2, whereas Shc-R401K and Shc-PI showed
a reduced ability to co-immunoprecipitate with RET/PTC2, 40% and 10% residual
binding compared to wild-type Shc, respectively (II, Fig. 4B). Over-expression of
either wild-type Shc or mutant Shc proteins also reduced phosphorylation levels of
endogenous Shc (II, Fig. 4C). When the ability to interact with Sos was tested, only
the Shc-Y317F mutant impaired the recruitment of Sos and ERK activation (II, Fig.
5). These results indicate that the Tyr317 of Shc has a major role in coupling RET
signalling to the Grb2-Sos pathway in our cell model system.
To determine whether the transforming activity of RET/PTC2 is dependent
on the activation of Shc, NIH 3T3 cells co-expressing RET/PTC2 and the
interfering mutant Shc-Y317F were examined for their ability to form foci of
transformed cells. A reduction of 70-80% in transformed foci formation was
obtained (II, Fig. 6). A minor reduction of RET/PTC2 transforming activity was
also observed in cells co-expressing RET/PTC2 and wild-type Shc or Shc-PI.
Altogether, these results suggest that competition by exogenous Shc with other
transducers is minimal. The loss of transforming activity is mainly due to the
impairment of Grb2-Sos recruitment and ERK activation by the Shc-Y317F
mutant. Our findings support a major role for Shc in RET-mediated cell-
transformation, possibly via the Ras/ERK pathway.
Interestingly, during the 5 weeks time period needed for assessing foci
formation, NIH 3T3 cell lines co-expressing RET/PTC2 and Shc-Y317F reverted
to a flat morphology, grew in a more organised fashion characteristic of non-
transformed fibroblasts (II, Fig. 6). At a later time, week 5 to 9 after transfection,
10-15% of the cells died (II, Table 2). Interaction between Shc and Grb2-Sos and
the activation of ERK were impaired in these cells (II, Fig. 8). The cell death effect
was most probably caused by the co-expression of SHC-Y317F and RET/PTC2
genes. Cell proliferation and cell death are opposing cellular processes. However,
signalling between the proliferation and cell death machinery occurs and a strong
oncogenic stimulus to proliferate may associate with an increased sensitivity to
apoptosis (Guo and Hay, 1999). One might speculate that the imbalance in the
signalling pathways due to Shc-Y317F over-expression potentiates death
signalling, usually masked by proliferative pathways. This hypothesis, with
intriguing therapeutic implications, needs to be carefully investigated. Pro-
apoptotic signals might also be the consequence of cell stress due to incorrectly
transduced RET/PTC2 signalling. Reduction of transforming activity and induction
of cell death were also observed in cells co-expressing SHC-Y317F with TRK-T3
oncogene (Roccato et al., 2002), indicating the existence of a mechanism shared by
other RTK oncogenes.
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4.2 ALTERNATE SPLICING INFLUENCES RET SIGNALLING POTENTIAL
(I, III)
Activation of RET, either by ligand or through specific mutations, results in
phosphorylation of multiple tyrosine residues that in turn, interact with specific
adaptor molecules to trigger downstream signalling. In response to these signals,
cell type-specific responses are initiated that implement the multiple functions of
RET. An additional level of complexity of RET signalling is added by alternative
splicing of the RET gene, which leads to two functionally distinct RET isoforms
with different signalling potential. Indeed, RET9 and RET51, although sharing
identical extracellular domains, do not complex with each other upon activation in
sympathetic neurons (Tsui-Pierchala et al., 2002a). A differential localisation of
RET9 and RET51 within neurons or mechanisms regulated by either the 9- or 51-
amino acid regions unique to these isoforms may account for their lack of
association. RET9 and RET51 also show different tyrosine-phosphorylated
associated proteins (Tsui-Pierchala et al., 2002a). Tyr1096, present only in RET51,
has been shown to bind Grb2, which activates PI3K and Ras/MAPK pathways
(Alberti et al., 1988; Besset et al., 2000; Myers and Mulligan, 2004). In addition,
RET9 and RET51 differ in protein interactions with Tyr1062, which is the docking
site for multiple adaptor proteins including Shc and it is also the penultimate amino
acid common to both isoforms. The binding of signalling molecules to RET9 and
RET51 varies both quantitatively and qualitatively. For instance, Shc binds both
RET9 and RET51 but, whereas RET51 binds only to the PTB(Shc) domain, RET9
can also bind through the SH2(Shc) domain (I, Fig. 3B; Lorenzo et al., 1997). In
order to investigate the effects of differential RET signalling promoted by the two
isoforms and the role of the Tyr1062 multidocking site, we analysed long-term
cellular responses to ligand-dependent activation of RET.
4.2.1 Tyr1096 functionally substitutes the Tyr1062 multidocking site in RET-
dependent scattering
To compare the biological effects of RET9 and RET51 in a neural cell
environment, we used neuroepithelioma SK-N-MC cells that endogenously express
GFRand GFR co-receptors. We generated SK-N-MC cell lines stably
expressing either the short or long isoform of RET. When stimulated by GDNF or
NRTN, RET-expressing SK-N-MC cells lose their epithelial features, reduce
growth rate, alter their morphology, dissociate and begin to scatter (III, Fig. 1).
Treatment of RET-expressing SK-N-MC cells with a chemical inhibitor of the
kinase activity of RET (Lanzi et al., 2000) completely prevented cell scattering,
indicating that kinase activity of RET is required for this cellular response.
To determine whether multidocking site Tyr1062 of RET is required for
cell scattering, we generated SK-N-MC cell lines expressing either the short or
long isoform of RET devoid of Tyr1062. Unexpectedly, RET51-Y1062F-
expressing cells were able to scatter upon GDNF stimulation, although to a lesser
extent than wild-type RET51-expressing cells. In contrast, RET9-Y1062F-
expressing cells were totally impaired in cell movement assay (III, Fig. 2). Tyr1096
is present only in RET51. The substitution of tyrosine with phenylalanine at codon
1096 barely affected RET51-dependent cell scattering. Only the double mutant
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RET51-Y1062F/Y1096F, devoid of both Tyr1062 and Tyr1096, prevented cell
scattering. Overall, these results suggest that the Tyr1096 functionally substitutes
for Tyr1062 multidocking site in RET-dependent cell scattering.
4.2.2 RET-dependent cell scattering and phosphorylation of Shc, Akt, ERK1/2, and
p38
Ras/ERK, PI3K/Akt, and p38 signalling pathways are activated via Tyr1062 of
RET (Besset et al., 2000; Hayashi et al., 2000, 2001; Segouffin-Cariou and
Billaud, 2000). However, the mutation of Tyr1062 only partially affects the
PI3K/Akt pathway, which can be activated via Tyr1096 (Besset et al., 2000). To
address the question of which biochemical pathways play a role in RET-dependent
cell scattering, we analysed the phosphorylation of Shc, Akt, ERK1/2, and p38
signal transducers in RET-expressing SK-N-MC cells (III, Fig. 3). Shc, Akt,
ERK1/2, and p38 proteins were phosphorylated in all GDNF-stimulated cells
expressing RET with a functional phosphorylated Tyr1062. The presence of the
tyrosine to phenylalanine mutation at codon 1062 in the short but not in the long
long isoform of RET prevented their activation. Simultaneous substitution of both
Tyr1062 and Tyr1096 was required for preventing RET51 signalling to Akt,
ERK1/2, and p38. Taken together, these results reveal a correlation between the
scattering response and the activation of Shc, Akt, ERK1/2, and p38 pathways.
Moreover, the existence of alternative pathways for Akt, ERK, and p38 activation
independent of Tyr1062 phosphorylation suggests that Tyr1062 and Tyr1096 may
activate redundant signalling pathways leading to cell scattering.
To further analyse the role of these signalling pathways, we used specific
chemical inhibitors of Akt, ERK1/2, and p38 (III, Fig. 4). Each inhibitor caused a
partial but significant inhibition of cell scattering. However, none was able to
completely block cell scattering. Thus, each of these pathways, Akt, ERK1/2, and
p38, is likely necessary but not sufficient for inducing RET-dependent cell
scattering.
4.2.3 Tyr1096 functionally substitutes the Tyr1062 in RET-dependent cell
branching
The MDCK dog kidney epithelial cells have been extensively used for studying the
molecular mechanisms of branching morphogenesis. Hepatocyte growth factor
(HGF), the ligand for Met receptor tyrosine kinase (Naldini et al., 1991), induces
scattering, chemotactic movements, and tubule formation of MDCK cells (Stoker
et al., 1987; Montesano et al., 1991). In the presence of soluble GFR1 (sGFR1),
RET-expressing MDCK cells respond to GDNF in a similar manner as parental
MDCK cells respond to HGF (Tang et al., 1998). To rule out the possibility that
RET Tyr1062 and Tyr1096 function in cell differentiation processes was restricted
to a particular cell type or cell line, we established MDCK cell lines expressing
RET9, RET51, or RET mutants devoid of Tyr1062, Tyr1096, or both residues, and
analysed their ability to form branching tubules in collagen gels in response to
GDNF/sGFR1 (III, Fig. 2). In line with the results obtained using neuronal cells,
the mutation of Tyr1062 impaired branching morphogenesis of RET9-expressing
cells, whereas only simultaneous mutation of Tyr1062 and Tyr1096 prevented
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RET51-dependent cell branching (III, Fig. 5). Thus, Tyr1096 functionally
substitutes for Tyr1062 to induce differentiation events in MDCK cells.
4.2.4 RET-dependent branching of MDCK cells requires Grb2-coupled pathways
Thus far, Grb2 is the only transducer known to directly bind Tyr1096 of RET,
while it is recruited to Tyr1062 via Shc or FRS2 (I, Liu et al., 1996; Alberti et al.,
1998; Kurokawa et al., 2001). The substitution of tyrosine 1096 with phenylalanine
strongly reduces, and the simultaneous mutation of both Tyr1062 and Tyr1096
completely abolishes Grb2 binding to RET51 (Liu et al., 1996; Alberti et al., 1998;
III, data not shown). To determine whether Grb2 plays a role in promoting cell
branching, we transiently expressed a dominant-negative Grb2 mutant (DN-Grb2)
(Tanaka et al., 1995) in MDCK(RET) cells in order to interfere with signalling
pathways triggered by Tyr1096. The expression of DN-Grb2 in MDCK(RET) cells
expressing wild-type RET9 or RET51 caused a partial reduction of GDNF-
dependent branching morphogenesis (III, Fig. 6). Reduction, but not abrogation, of
cell branching was observed in GDNF-stimulated MDCK(RET51-Y1062F) cells.
MDCK(RET51-Y1096F) cells were unable to form branching tubules. These
results suggest that other unknown molecules besides Grb2 may have the ability of
binding Tyr1096. The partial reduction of branching activity displayed by cells
expressing RET9 might result from the differences between RET9 and RET51
amino acid sequence surrounding Tyr1062. Indeed, Tyr1062 in the short and long
isoform does appear to have differential interactions with Shc and Enigma proteins
(Lorenzo et al., 1997; Borrello et al., 2002). Consequently, the Tyr1062 of RET9
might be able to selectively activate unidentified transducers, possibly different
from Grb2, which are required to induce cell-branching activity. This ability of the
two RET isoforms to differentially recruit signalling transducers involved in
differentiation pathways may provide a biochemical basis for the functional
differences between RET9 and RET51 in vivo (Srinivas et al., 1999; de Graaff et
al., 2001). Our results also indicate that Grb2 plays a crucial role in these
pathways.
4.2.5 Tyr1062 is required for transforming activity of both RET isoforms
To further characterise the role of Tyr1062 in the context of the RET isoforms, we
analysed the transforming potential of RET9 and RET51 simultaneously carrying
two mutations; C634R, associated with MEN 2A, and Y1062F. The expression
constructs RET9-634R/1062F and RET51-634R/1062F were used in a focus
formation assay with NIH 3T3 cells. The transforming activity of both RET9-
C634R/Y1062F and RET51-C634R/Y1062F was strongly reduced compared with
that of the oncogenic RET-C634R proteins with a functional Tyr1062 multidocking
site (III, Fig. 7). Thus, unlike cell scattering and branching morphogenesis
induction, Tyr1062 is required by both oncogenic RET-C634R isoforms for
promoting transformation of NIH 3T3 cells. In addition, our findings indicate that
signalling pathways activated via Tyr1062 and Tyr1096 required for the
transforming activity of oncogenic RET proteins are not redundant.
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4.3 RET-DEPENDENT AND RET-INDEPENDENT SIGNALLING
PATHWAYS IN TUMOR BIOLOGY AND DEVELOPMENTAL BIOLOGY (IV,
V)
The characterisation of RET-mediated signalling pathways is important for
understanding the biological effects induced by different forms of RET activation,
which shape the nervous system and the kidney during normal embryogenesis
and/or contribute to the development of cancer and congenital malformations under
aberrant RET activation. Elucidation of the genetic mechanisms of aberrant RET
activation and their functional consequences can give clues to understanding the
systems disrupted in cancer syndromes and, in turn, implications for developmental
or survival processes.
4.3.1 RET kinase activity and PLCsignalling are impaired by HSCR mutations
and activated by MEN 2 mutations
There appears to be a correlation between specific types of RET mutation and the
clinical phenotypes. The genotype/phenotype associations reflect differences in
behaviour and function among the mutant RET proteins. MEN 2 mutations convert
RET to a dominantly acting transforming gene, whereas HSCR mutations disable
the activation or expression of RET and impair its function. However, a simple
activating versus inactivating model of gene action is not sufficient to explain the
co-segregation of MEN 2A/FMTC with HSCR in patients with a single point
mutation at residues 609, 611, 618, or 620 (Chappuis-Flament et al., 1998;
Takahashi et al., 1999).
In order to analyse the biological effects of loss-of-function and gain-of-
function mutations of RET, associated with either MEN 2 or HSCR, or both, we
introduced mutations identified in patients with HSCR or MEN 2A/FMTC to the
coding sequence of the short isoform of RET by site-directed mutagenesis and
assessed the kinase activity of the RET mutant proteins transiently expressed in
293T cells. The mutation at Cys620 causes both MEN 2A/FMTC and HSCR, albeit
with low penetrance, in a sizeable fraction of families. Hence, the name Janus, like
the double-faced Roman god. Gain-of-function Janus-C620R, MEN 2A-C634R,
and FMTC-E768D mutations activated, whereas HSCR-associated S765P and
S767R mutations reduced the kinase activity of RET (IV, Fig. 2A).
The PLCpathway is impaired by HSCR-associated mutations (Iwashita et
al., 2001). In line with previous studies, we found that phosphorylation of PLC
was induced in cells expressing RET, Janus-C620R, MEN 2A-C634R, or FMTC-
E768D, whereas it was undetectable in cells expressing the HSCR-S765P or
HSCR-S767R proteins (IV, Fig. 2B). Thus, complete or partial loss of RET kinase
activity and disruption of PLCsignalling are functional consequences of the
S765P- and S767R-HSCR mutations.
4.3.2 Janus-C620R dimers are unresponsive to GDNF
To analyse the biological effects of loss-of-function and gain-of-function mutations
in RET, we established stable MDCK cell lines expressing wild-type and mutant
RET proteins (IV, Fig. 3A). We first characterised the GDNF-responsiveness of
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RET proteins. RET phosphorylation was observed after 2 hours of GDNF/sGFR1
treatment (IV, Fig. 3B); the delay is most probably due to the kinetics of
GDNF/sGFR1 association in solution. The phosphorylation of the Janus-C620R
protein either in the absence or in the presence of ligand was low, suggesting that
the covalent dimers formed by Janus-C620R were unresponsive to GDNF (IV, Fig.
3C). In contrast, the MEN 2A dimers were sensitive to GDNF. They were highly
autoactive, and exhibited an increase in the level of tyrosine phosphorylation upon
ligand stimulation. Both HSCR-RET proteins failed to respond to GDNF, whereas
the gain-of-function FMTC-E768D protein was highly responsive to the ligand.
4.3.3 Janus-C620R and HSCR mutations impair motility and migration, epithelial
tubule formation and protection from apoptosis of GDNF-stimulated RET-
expressing cells
RET-MDCK cells exhibit increased motility, cell dissociation, and directed
migration in response to GDNF/sGFR1. In order to compare the biological
consequences of RET mutations, we studied enhanced cellular motility, also called
chemokinesis, and guided migration toward a chemoattractant, referred to as
chemotaxis, of RET-expressing MDCK cells by the Boyden dual chamber assay.
Motility and directed migration were fully abolished in MDCK cells expressing
Janus-C620R and HSCR proteins (IV, Fig. 4). In contrast, MEN 2A-C634R-
expressing cells migrated even without stimulation by the ligand, which was able to
further enhance cellular motility and guided migration. Chemotaxis and
chemokinesis of FMTC-E768D-expressing cells were also ligand-dependent.
To further analyse the effects of the mutations on RET-promoted cellular
activities, we examined the ability of RET-MDCK cells to form branching tubules
in three-dimensional collagen gels. This property of MDCK cells is considered as
an epithelial tubulogenesis model, which resembles branching of developing
ureteric buds (Montesano et al., 1991; Tang et al., 1998; Comoglio and Trusolino,
2002). The Janus-C620R mutation allowed only poor branching of RET-MDCK
cells and HSCR-associated mutations entirely abolished branching morphogenesis
(IV, Fig. 5). The MEN 2A-C634R mutation promoted a constitutive ligand-
independent branching activity, which was further potentiated by GDNF. The
FMTC-E768D mutation is a gain-of-function mutation with a poor oncogenic
potential and transforming activity in fibroblasts in the absence of GDNF (Pasini et
al., 1997; Iwashita et al., 1999). Indeed, the FMTC-E768D protein was unable to
induce branching of MDCK cells in the absence of GDNF.
Apoptosis induced due to the absence of cell-matrix interactions (also
called anoikis) was analysed to determine whether the RET mutations affect the
sensitivity to cell death. Normal cell matrix-interactions were disrupted by plating
cells on culture dishes coated with poly-hydroxyethylmethacrylate to prevent cell
attachment, and apoptotic cells were identified by TUNEL. Anoikis was
significantly alleviated by GDNF in RET-expressing MDCK cells (IV, Fig. 6).
Cells expressing the Janus-C620R and HSCR proteins were not protected from
apoptosis by the RET ligand. Moreover, GDNF rescued from apoptosis MDCK
cells expressing MEN 2A-C634R and FMTC-E768D. Thus, inability to migrate
and branch in response to GDNF and sensitivity to apoptosis are features shared by
Janus-C620R- and HSCR-RET-expressing cells.
61
4.3.4 Janus-C620R and MEN 2A-C634R promote rapid cell proliferation and form
colonies in soft agar
MDCK cells are epithelial cells that exhibit features common to the process of
tumorigenesis when disruption of cell-cell contacts, increased cell motility,
enhanced proliferation and ability to grow in soft agar are induced, leading to the
transition from an epithelial to a mesenchymal phenotype (Comoglio and
Boccaccio, 2001). We analysed GDNF-induced proliferation of cells expressing
wild-type and mutant RET proteins. Janus-C620R-expressing cells showed ligand-
independent high proliferative activity that was not further increased by the ligand
(IV, Fig. 7). A similar ligand-independent high proliferative rate was observed in
MEN 2A-C634R-expressing cells. Cells expressing wild-type or FMTC-E768D
proteins increased their growth rate only in the presence of the ligand. In contrast,
no increase in growth rate was displayed by HSCR-RET-expressing cells.
To determine whether the Janus-C620R protein has the ability to transform
cells, we performed soft-agar assays and compared the colony-forming efficiency
of Janus-C620R- and MEN 2A-C634R-expressing cells to that of wild-type RET-
expressing cells. Janus-C620R cells formed colonies, but with a lower efficiency
and longer latency than MEN 2A-C634R cells (IV, Fig. 8). Wild-type RET cells
did not form colonies in soft agar. Thus, the covalent dimerization of Janus-C620R
confers ligand-independent rapid proliferation activity and anchorage-independent
growth. These ligand-independent activities apparently account for the oncogenic
capacity associated with the Cys620 mutation and may be responsible for C cell
hyperplasia and tumor development. Our findings may also explain why the MEN
2A-C634R mutation does not associate with HSCR (Eng et al., 1996a). Unlike the
Janus-C620R dimers, MEN 2A-C634R dimers are responsive to GDNF and
promote migration, branching, and protection from apoptosis. The ability of MEN
2A-C634R cells to respond to GDNF might allow MEN 2A-C634R-expressing
enteric nervous system progenitors to undergo GDNF-induced migration toward
and within the gut wall. Indeed, MEN 2A-C634R dimers in neuroectodermal cells
are also inducible by GDNF (Mograbi et al., 2001).
Previous and our results suggest that the autokinase and kinase activity of
RET and its full glycosylation and ability to reach the cell membrane, as well as its
responsiveness to GDNF, all affect the functional consequences of RET mutations.
One may speculate that different MEN 2 phenotypes are determined by constitutive
RET activation at a different intensity and with different mechanisms (MEN 2A vs.
MEN 2B), associated with the availability of GDNF in different tissues.
Furthermore, the level of expression of GFRαs, which may interfere in the RET 
dimerisation (Kawai et al., 2000), and other GFLs may play a role in determining
the clinical phenotype of MEN 2.
Hyperplasia of the thyroid C cells is due to hyperactive RET signalling
during development of the thyroid gland. The complete MEN 2A phenotype is
associated with a high activation of RET, which can be further enhanced by
binding of the ligand, if available. Cells expressing the MEN 2A-C634R protein
were constitutively active in all biological assays. Mutations in non-cysteine
domains of RET causing FMTC are associated with a much lower level of RET
activation. The presence of GDNF may be critical for a full activation, at least for
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the mutation at glutamic acid residue 768 in vitro. Interestingly, among the
alterations at residue 634, the mutation that changes cysteine to ariginine (C634R)
has not been found in families with FMTC (Eng et al., 1996a). The speed of
malignant transformation apparently correlates with the level of constitutive RET
activation. The MEN 2A-C634R mutation accounts for the very early onset of
MTC, and the FMTC-E768D mutation results in an attenuated form with late onset
(Machens et al., 2001).
The features of the Janus-C620R protein support a model in which the
degree of RET signalling during development may explain the coexistence of MEN
2 with HSCR (Ponder, 1999). The low autophosphorylation level of Janus-C620R
compared with MEN 2A-C634R dimers and the lack of GDNF-induced activities
such as chemotactic migration and differentiation, are characteristic of HSCR-
associated mutations, whereas anchorage-independent growth and rapid
proliferation of cells are features associated with oncogenic mutations of RET.
Thus, one may speculate that high RET activity of Janus-C620R during
embryogenesis may be sufficient to initiate C cell hyperplasia, but without ligand
responsiveness the Janus-C620R protein is not able in some genetic backgrounds to
drive the migration of enteric neuroblasts towards ligand gradient.
4.3.5 RET-independent morphological responses to GDNF: restoration of the renal
phenotype of Ret-deficient mice and induction of branching of gfr1-MDCK cells
There is evidence that GFR1 may have RET-independent roles; Ret and gfr1
expression patterns do not overlap in many tissues (Sainio et al., 1997; Golden et
al., 1999); GDNF binds to GFR1 and can signal in the absence of RET (Jing et
al., 1996; Poteryaev et al., 1999; Trupp et al., 1999). Our observation that the
ureteric branching morphogenesis of Ret-deficient mice was partially restored in
organ culture when GDNF was added to the culture medium, prompted us to
investigate the role and mechanism of GFR1 in branching morphogenesis.
To analyse the possible role of RET-independent, GFR1-mediated
signalling in ureteric budding and branching during nephrogenesis, we tested the
ability of exogenous GDNF to induce ureteric budding or sustain its branching in
Ret-deficient mice. Embryonic day (E)11 Ret-/- urogenital blocks including kidney
rudiments were cultured with or without GDNF. In the presence of GDNF, the
number of ureteric bud tips in the hypodysplastic kidneys of Ret-/- mice increased,
although not to the level seen in Ret+/+ kidneys (V, Fig. 1). Exogenous GDNF
increased the number of ureteric bud tips in Ret-/-, Ret+/-, and wild-type kidney
explants. However, with or without exogenous GDNF, the number of Ret-/-
urogenital explants completely lacking a ureteric bud remained the same (V, Table
1). These results indicate that RET-independent signalling by GDNF rather sustains
the ureteric branching than initiates bud formation from the Wolffian duct.
In order to study the possible mechanism and mode of action of GDNF in
GFR1 and RET/GFR1 signalling, we generated MDCK cells lines expressing
RET and GFR1 or GFR1 only with or without fused green fluorescent protein
(GFP). The possible endogenous Ret expression by MDCK cells was excluded by
Northern blot and RT-PCR analysis. In the presence of GDNF, both GFR1- and
RET/GFR1-MDCK cells formed branching tubules (V, Fig. 2). The branching
response of GFR1-expressing cells was highly sensitive, since already 0.1 pg/ml
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of GDNF evoked tubulogenesis. In contrast, RET/GFR1-expressing cells started
to branch only at 0.1 ng/ml of GDNF.
To further characterise the ability of GFR1-MDCK cells to respond to
GDNF, we analysed both chemotactic migration and chemokinesis of GFR1- and
RET/GFR1-expressing cells. Two different chemotaxis assays were performed;
the Boyden dual chamber assay and agarose beads soaked in GDNF (Tang et al.,
1998). GDNF was chemotactic for RET/GFR1-MDCK cells (V, Fig. 3). In
contrast, GFR1-expressing cells did not show any chemotactic response to
GDNF. Only a weak chemokinetic response was observed. Altogether, these results
indicate that different concentrations of GDNF and the receptor context define the
cellular responses to the ligand. Low concentrations of GDNF induce branching
but not chemotaxis of GFR1-expressing, Ret-deficient MDCK cells. When RET
is present, GDNF induces both branching and chemotaxis but only at a high
concentration. Thus, RET appears to negatively control branching at low
concentrations of GDNF. The GFR1-RET complex may be less stable than the
GFR1 complex, which may increase the GDNF binding sites in the absence of
RET and initiate the branching response at low GDNF concentrations. It is also
possible that the GFR1-RET complex is internalised without ligand faster than the
GFR1 complex. On the other hand, it is apparent that RET is essential for the
chemotactic response to GDNF, suggesting that in the embryonic kidney the proper
orientation of the tips of the ureteric buds within the nephrogenic mesenchyme
might be critically controlled by RET activity.
4.3.6 GDNF activates Met in both RET-dependent and -independent signalling
most likely by Src family kinases
Met is the only endogenous receptor known to promote tubule formation of
parental MDCK cells (Santos et al., 1993). The similarity of the GDNF- and HGF-
induced branching responses of MDCK cells prompted us to study the possible
interplay of GDNF and Met. We analysed Met phosphorylation by GDNF in
GFR1- and RET/GFR1-MDCK cells. In 15 min, GDNF evoked Met
phosphorylation in GFR1- and RET/GFR1-expressing MDCK cells but not in
parental MDCK cells (V, Fig. 4). Saturation was reached at 0.1 pg/ml. In
RET/GFR1-MDCK cells, RET was phosphorylated already at 0.1 pg/ml of
GDNF, and saturation was reached at 10 ng/ml. Met activation by GDNF was not
restricted to a particular cell line or cell type, since GDNF also induced rapid Met
phosphorylation in human neuroblastoma SHEP cells, which express GFR1 but
not RET, in gfr1-transfected COS7 cells, and NIH 3T3 cells.
In a series of cross-linking immunoprecipitation experiments, we tested
whether GDNF activates Met directly or indirectly. A direct association between
the GDNF receptor complex and Met was not detected (V, Fig. 5 and unpublished
data), making a direct interaction between GDNF and Met highly unlikely.
Src-type kinases were putative candidates to mediate the GDNF signalling
from GFR1 to Met. Src-type kinases like GFR1 are associated with the lipid
rafts (Harder et al., 1998); they are activated in RET-independent signalling by
GDNF (Poteryaev et al., 1999; Trupp et al., 1999); c-Src associates with Met after
receptor activation (Rahimi et al., 1998); and integrin-mediated activation of Ron
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receptor tyrosine kinase, homologous to Met, requires c-Src (Danilkovitch-
Miagkova et al., 2000). Indeed, we found that already 0.1 pg/ml of GDNF saturated
Src phosphorylation, demonstrating Src phosphorylation in both GFR1- and
RET/GFR1-expressing MDCK cells (V, Fig. 6). By using the Src-type kinase
inhibitor PP2 and adenoviruses to introduce DN c-Src, we blocked Src
phosphorylation and Met activation induced by GDNF but not that induced by
HGF (V, Fig. 7A). Expression of adenovirus-targeted activated c-Src resulted in
GDNF-independent phosphorylation of Met, which could not be further increased
by GDNF. In contrast, HGF enhanced Met phosphorylation in wild-type MDCK-
expressing activated c-Src. Moreover, DN c-Src suppressed GDNF- but not HGF-
induced branching tubulogenesis of GFRand RET/GFRMDCK cells (V,
Fig. 7B). Activated c-Src evoked branching in a ligand-independent manner in all
tested MDCK lines. In the presence of activated c-Src, HGF but not GDNF further
increased the number of branching tubules. These findings indicate that Src family
kinases are upstream to Met in GDNF-induced activation but downstream to Met in
HGF-induced activation. The in vivo contribution of GDNF/Met signalling in
kidney morphogenesis and the role of Src-type kinases will be further elucidated by
conditional Met-deficient and RET/Met- vs. RET-deficient mice.
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5. CONCLUDING REMARKS AND PERSPECTIVES
The results of the current study as well as previous data indicate that Shc activation
plays a key role in the transforming pathways triggered by RET oncoproteins. The
co-expression of oncogenic RET with a dominant negative Shc-Y317F protein was
found to revert the transformed phenotype of cells and induce cell death. RET is a
potential target for a selective cancer-therapy approach. Indeed, various strategies
have been used to block the activity of RET in pre-clinical models. Retrovirus
vector-mediated RNA interference might represent an alternative for the
development of gene therapeutic approaches to block oncogenic RTK signalling.
We showed that tyrosine 1062 is differentially required by the RET
isoforms to activate pathways leading to cell differentiation. In contrast, there was
no redundancy of pathways leading to cell transformation via tyrosine 1062. We
provide evidence of differential recruitment of signalling molecules involved in
differentiation pathways by RET9 and RET51, strengthening the possible existence
of distinct differentiative potentials of the RET isoforms. It will be interesting to
expand these studies and compare gene expression profiles associated with either
RET9 or RET51 in kidney and neural cell types.
The challenges ahead involve defining the downstream effectors of
RET/PTC other than Shc and the MAPK pathway involved, especially, in thyroid
cell transformation and papillary carcinoma development. Gene expression
microarray analyses will allow us to evaluate targets of RET/PTC in human thyroid
cells expressing retrovirus-targeted RET/PTC, and in tumors carrying RET/PTC
rearrangements.
Our results and previous data suggest that the autokinase and kinase activity
of RET, its full glycosylation and ability to reach the cell membrane, as well as its
responsiveness to GDNF, all affect the functional consequences of RET point-
mutations. We propose a model to explain how a single mutation in RET can lead
to opposing disease phenotypes and why the MEN 2A-C634R mutation does not
associate with HSCR. The next step is to study the relationship between RET and
cancer development or congenital malformation in a physiological proper
environment such as neural crest cells.
We observed RET-independent morphological responses to GDNF in
kidney culture. Recently RET-independent GFRα1 signaling has been shown to be 
dispensable for proper development and physiological function (Enomoto et al.,
2004). However, RET-independent GDNF signalling can potentially occur and
play a role in the horizontal interplay between GDNF/GFR1 and Met signalling
systems. The in vivo contribution of GDNF/Met signalling during development and
the role of Src-type kinases will be elucidated by conditional Met-deficient and
RET/Met- vs. RET-deficient mice.
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